



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12N 15/55, C07K 16/40, C12N 9/12, G01N 33/50		A2	(11) International Publication Number: WO 00/08180 (43) International Publication Date: 17 February 2000 (17.02.2000)
(21) International Application Number: PCT/US99/17630		#9 attachment 09/989 474	
(22) International Filing Date: 03 August 1999 (03.08.1999)		Published	
(30) Priority Data: 60/095,270 04 August 1998 (04.08.1998) US 60/099,972 11 September 1998 (11.09.1998) US			
(60) Parent Application or Grant IMMUNEX CORPORATION [/]; (O) VIRCA, G., Duke [/]; (O) BIRD, Timothy, A. [/]; (O) ANDERSON, Dirk, M. [/]; (O) MARKEN, John, S. [/]; (O) VIRCA, G., Duke [/]; (O) BIRD, Timothy, A. [/]; (O) ANDERSON, Dirk, M. [/]; (O) MARKEN, John, S. [/]; (O) JONES, Simone, L. ; (O)			

(54) Title: HUMAN cDNAs ENCODING POLYPEPTIDES HAVING KINASE FUNCTIONS

(54) Titre: ADNc HUMAINS CODANT DES POLYPEPTIDES A FONCTIONS KINASENS

## (57) Abstract

The invention is directed to purified and isolated human polypeptides having kinase function, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, the use of such polypeptides and fragmented peptides in phosphorylation reactions and as molecular weight markers, the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, the use of such polypeptides in screening assays, and kits comprising these reagents.

## (57) Abrégé

La présente invention concerne des polypeptides humains isolés et purifiés à fonction kinase, les acides nucléiques codant ces polypeptides, des procédés de production de formes recombinées de ces polypeptides, des anticorps produits contre ces polypeptides, et des fragments de peptides obtenus à partir de ces polypeptides. Par ailleurs, cette invention concerne l'utilisation de ces polypeptides et des peptides fragmentés dans des réactions de phosphorylation et comme étalons de masse moléculaire, l'utilisation de ces polypeptides et des peptides fragmentés comme régulateurs de la fragmentation des peptides, l'utilisation de ces polypeptides dans des essais de dépistage, et enfin, des kits renfermant ces réactifs.

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 7 :</b> <b>C12N 15/55, 9/12, C07K 16/40, G01N 33/50</b>		<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/08180</b> <b>(43) International Publication Date:</b> 17 February 2000 (17.02.00)
<b>(21) International Application Number:</b> PCT/US99/17630			<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
<b>(22) International Filing Date:</b> 3 August 1999 (03.08.99)			
<b>(30) Priority Data:</b> 60/095,270 4 August 1998 (04.08.98) US 60/099,972 11 September 1998 (11.09.98) US			
<b>(71) Applicant (for all designated States except US):</b> IMMUNEX CORPORATION [US/US]; 51 University Street, Seattle, WA 98101 (US).			<b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> VIRCA, G., Duke [US/US]; 16690 S.E. 50th Place, Bellevue, WA 98006 (US). BIRD, Timothy, A. [GB/US]; 10804 Olallie Drive N.E., Bainbridge Island, WA 98110 (US). ANDERSON, Dirk, M. [US/US]; 3616 N.W. 64th Street, Seattle, WA 98107 (US). MARKEN, John, S. [US/US]; 11804 9th Avenue S.W., Seattle, WA 98146 (US).			
<b>(74) Agent:</b> JONES, Simone, L.; Immunex Corporation, Law Dept., 51 University Street, Seattle, WA 98101 (US).			

**(54) Title:** HUMAN cDNAs ENCODING POLYPEPTIDES HAVING KINASE FUNCTIONS**(57) Abstract**

The invention is directed to purified and isolated human polypeptides having kinase function, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, the use of such polypeptides and fragmented peptides in phosphorylation reactions and as molecular weight markers, the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, the use of such polypeptides in screening assays, and kits comprising these reagents.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KR	Kenya	NO	Norway	YU	Yugoslavia
CII	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**D scription**

**5**

**10**

**15**

**20**

**25**

**30**

**35**

**40**

**45**

**50**

**55**

## HUMAN cDNAs ENCODING POLYPEPTIDES HAVING KINASE FUNCTIONS

10

5

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is related to the U.S. provisional application serial number 60/095,270, filed on August 4, 1998, and U.S. provisional application serial number 60/099,972, filed September 11, 1998, and bearing the same title and listing the same inventors.

15

10

FIELD OF THE INVENTION

The invention is directed to purified and isolated human polypeptides having kinase function, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, the use of such polypeptides and fragmented peptides in phosphorylation reactions and as molecular weight markers, the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, the use of such polypeptides in screening assays, and kits comprising these reagents.

20

15

BACKGROUND OF THE INVENTION

The eukaryotic protein kinases make up a large and rapidly expanding family of proteins related on the basis of homologous catalytic domains. Spurred by the development of gene cloning and sequencing methodologies, distinct protein kinase genes have been identified from a wide selection of invertebrates and lower eukaryotes, including *Drosophila*, *Caenorhabditis elegans*, *Aplysia*, *Hydra*, *Dictyostelium*, and budding (*Saccharomyces cerevisiae*) and fission (*Schizosaccharomyces pombe*) yeast. Homologous genes have also been identified in higher plants. Protein kinases, however, are not limited to the eukaryotes. Enzyme activities have been well documented in prokaryotes, but the prokaryotic protein kinase genes are not obviously homologous to those of the eukaryotes. Because protein kinases are useful biochemical reagents, there is a need in the art for the continued discovery of unique members of the protein kinase family.

25

20

In addition, the discovery and identification of proteins are at the forefront of modern molecular biology and biochemistry. The identification of the primary structure, or sequence, of a sample protein is the culmination of an arduous process of

30

25

35

30

40

35

45

40

50

45

5

experimentation. In order to identify an unknown sample protein, the investigator can rely upon comparison of the unknown sample protein to known peptides using a variety of techniques known to those skilled in the art. For instance, proteins are routinely analyzed using techniques such as electrophoresis, sedimentation, chromatography, and mass spectrometry.

10

Comparison of an unknown protein sample to polypeptides of known molecular weight allows a determination of the apparent molecular weight of the unknown protein sample (T.D. Brock and M.T. Madigan, *Biology of Microorganisms* 76-77 (Prentice Hall, 6d ed. 1991)). Protein molecular weight standards are commercially available to assist in the estimation of molecular weights of unknown protein samples (New England Biolabs Inc. Catalog:130-131, 1995; J. L. Hartley, U.S. Patent No. 5,449,758). However, the molecular weight standards may not correspond closely enough in size to the unknown sample protein to allow an accurate estimation of apparent molecular weight.

15

The difficulty in estimation of molecular weight is compounded in the case of proteins that are subjected to fragmentation by chemical or enzymatic means (A.L. Lehninger, *Biochemistry* 106-108 (Worth Books, 2d ed. 1981)). Chemical fragmentation can be achieved by incubation of a protein with a chemical, such as cyanogen bromide, which leads to cleavage of the peptide bond on the carboxyl side of methionine residues (E. Gross, *Methods in Enz.* 11:238-255, 1967). Enzymatic fragmentation of a protein can

20

be achieved by incubation of a protein with a protease that cleaves at multiple amino acid residues (D. W. Cleveland et al., *J. Biol. Chem.* 252:1102-1106, 1977). Enzymatic fragmentation of a protein can also be achieved by incubation of a protein with a protease, such as *Achromobacter* protease I (F. Sakiyama and A. Nakata, U.S. Patent No.

25

5,248,599; T. Masaki et al., *Biochim. Biophys. Acta* 660:44-50, 1981; T. Masaki et al., *Biochim. Biophys. Acta* 660:51-55, 1981), which leads to cleavage of the peptide bond on the carboxyl side of lysine residues. The molecular weights of the fragmented peptides can cover a large range of molecular weights and the peptides can be numerous.

30

Variations in the degree of fragmentation can also be accomplished (D. W. Cleveland et al., *J. Biol. Chem.* 252:1102-1106, 1977).

35

40 The unique nature of the composition of a protein with regard to its specific amino acid constituents results in a unique positioning of cleavage sites within the protein. Specific fragmentation of a protein by chemical or enzymatic cleavage results in a unique "peptide fingerprint" (D. W. Cleveland et al., *J. Biol. Chem.* 252:1102-1106, 1977; M. Brown et al., *J. Gen. Virol.* 50:309-316, 1980). Consequently, cleavage at specific sites

45

50

55

5

results in reproducible fragmentation of a given protein into peptides of precise molecular weights. Furthermore, these peptides possess unique charge characteristics that determine the isoelectric pH of the peptide. These unique characteristics can be exploited using a variety of electrophoretic and other techniques (T.D. Brock and M.T. Madigan, *Biology of Microorganisms* 76-77 (Prentice Hall, 6d ed. 1991)).

10

When a peptide fingerprint of an unknown protein is obtained, this can be compared to a database of known proteins to assist in the identification of the unknown protein (W.J. Henzel et al., *Proc. Natl. Acad. Sci. USA* 90:5011-5015, 1993; B. Thiede et al., *Electrophoresis* 1996, 17:588-599, 1996). A variety of computer software programs

15

are accessible via the Internet to the skilled artisan for the facilitation of such comparisons, such as MultiIdent (Internet site: [www.expasy.ch/sprot/multiident.html](http://www.expasy.ch/sprot/multiident.html)), PeptideSearch (Internet site: [www.mann.embl-heidelberg.de...deSearch/FR\\_PeptideSearchForm.html](http://www.mann.embl-heidelberg.de...deSearch/FR_PeptideSearchForm.html)), and ProFound (Internet site: [www.chait-sgi.rockefeller.edu/cgi-bin/prot-id-frag.html](http://www.chait-sgi.rockefeller.edu/cgi-bin/prot-id-frag.html)). These programs allow the user to specify the cleavage agent and the molecular weights of the fragmented peptides within a designated tolerance. The programs compare these molecular weights to protein databases to assist in the elucidation of the identity of the sample protein. Accurate information concerning the number of fragmented peptides and the precise molecular weight of those peptides is required for accurate identification. Therefore, increasing the accuracy in the determination of the number of fragmented peptides and the precise molecular weight of those peptides should result in enhanced success in the identification of unknown proteins.

20

Fragmentation of proteins is further employed for the production of fragments for amino acid composition analysis and protein sequencing (P. Matsudiara, *J. Biol. Chem.*

25

262:10035-10038, 1987; C. Eckerskorn et al., *Electrophoresis* 1988, 9:830-838, 1988),

30

particularly the production of fragments from proteins with a "blocked" N-terminus. In addition, fragmentation of proteins can be used in the preparation of peptides for mass spectrometry (W.J. Henzel et al., *Proc. Natl. Acad. Sci. USA* 90:5011-5015, 1993; B.

35

Thiede et al., *Electrophoresis* 1996, 17:588-599, 1996), for immunization, for affinity

40

selection (R. A. Brown, U.S. Patent No. 5,151,412), for determination of modification

45

sites (e.g. phosphorylation), for generation of active biological compounds (T.D. Brock and M.T. Madigan, *Biology of Microorganisms* 300-301 (Prentice Hall, 6d ed. 1991)),

50

and for differentiation of homologous proteins (M. Brown et al., *J. Gen. Virol.* 50:309-316, 1980).

5

In view of the continuing interest in protein research and the elucidation of protein structure and properties, there exists a need in the art for polypeptides having kinase function or suitable for use in peptide fragmentation studies and in molecular weight measurements.

10

5

### SUMMARY OF THE INVENTION

The invention aids in fulfilling these needs in the art. The invention encompasses an isolated human nucleic acid molecule comprising the DNA sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 13, or 15 and an isolated human nucleic acid molecule encoding the amino

10 acid sequence of SEQ ID NO:7, 8, 9, 10, 11, 12, 14, or 16. The invention also encompasses nucleic acid molecules complementary to these sequences. As such, the 20 invention includes double-stranded nucleic acid molecules comprising the DNA sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 13, or 15 and isolated nucleic acid molecules encoding the amino acid sequence of SEQ ID NO:7, 8, 9, 10, 11, 12, 14 or 16. Both single-stranded

25 and double-stranded RNA and DNA nucleic acid molecules are encompassed by the invention. These molecules can be used to detect both single-stranded and double-stranded RNA and DNA variants encompassed by the invention. A double-stranded DNA probe allows the detection of nucleic acid molecules equivalent to either strand of the nucleic acid molecule. Isolated nucleic acid molecules that hybridize to a denatured, 30 double-stranded DNA comprising the DNA sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 13, or 15, or an isolated nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:7, 8, 9, 10, 11, 12, 14, or 16 are within the invention. A preferred set of hybridization 35 conditions are those of moderate stringency: in 50% formamide and 6XSSC, at 42°C with washing conditions of 60°C, 0.5XSSC, 0.1% SDS.

40 25 The invention further encompasses isolated nucleic acid molecules derived by *in vitro* mutagenesis from SEQ ID NO:1, 2, 3, 4, 5, 6, 13, or 15. *In vitro* mutagenesis would include numerous techniques known in the art including, but not limited to, site-directed mutagenesis, random mutagenesis, and *in vitro* nucleic acid synthesis. The invention also encompasses isolated nucleic acid molecules degenerate from SEQ ID NO:1, 2, 3, 4, 5, or 45 30 6 (and the resulting amino acid sequence) as a result of the genetic code, isolated nucleic acid molecules that are allelic variants of human DNA of the invention, or a species homolog of DNA of the invention. The invention also encompasses recombinant vectors that direct the expression of these nucleic acid molecules and host cells transformed or 50 transfected with these vectors. In addition, the invention encompasses methods of using

5

the nucleic acid noted above in assays to identify chromosomes, map human genes, and study tumors.

10

The invention also encompasses isolated polypeptides encoded by these nucleic acid molecules, including isolated polypeptides having a molecular weights as determined

5 by SDS-PAGE, isolated polypeptides in non-glycosylated form, and fragments thereof.

The invention further includes synthetic polypeptides encoded by these nucleic acid molecules. Peptides and fragments of these polypeptides, however derived, are also part of the invention and may be produced by any standard means, from chemical, enzymatic, recombinant, or synthetic methods. Isolated polyclonal or monoclonal antibodies that

10 bind to these polypeptides are encompassed by the invention. The invention further encompasses methods for the production of polypeptides having kinase functions

15 including culturing a host cell under conditions promoting expression and recovering the polypeptide from the culture medium. Especially, the expression of polypeptides having kinase functions in bacteria, yeast, plant, insect, and animal cells is encompassed by the

20 invention.

25 In general, the polypeptides of the invention having kinase function can be used to phosphorylate target proteins and to radiolabeled target proteins with  $^{32}\text{P}$ . In addition, the polypeptides of the invention having kinase function can be used to identify proteins having a phosphate activity.

30 20 In addition, assays utilizing polypeptides having kinase functions to screen for potential inhibitors of activity associated with polypeptide counter-structure molecules, and methods of using polypeptides having kinase functions as therapeutic agents for the treatment of diseases mediated by polypeptide counter-structure molecules are

35 25 encompassed by the invention. Methods of using polypeptides having kinase functions in the design of inhibitors thereof are also an aspect of the invention. The invention further encompasses use of polypeptides of the invention to screen for agonists and antagonists.

40 45 The invention further encompasses the fragmented peptides produced from polypeptides of the invention by chemical or enzymatic treatment. In addition, the polypeptides of the invention and fragmented peptides thereof, wherein at least one of the sites necessary for fragmentation by chemical or enzymatic means has been mutated, are an aspect of the invention.

50 The invention further includes a method for using these polypeptides and fragmented peptides thereof as molecular weight markers that allow the estimation of the molecular weight of a protein or a fragmented protein sample. The invention also

5

encompasses a method for the visualization of the molecular weight markers of the invention thereof using electrophoresis. The invention further encompasses methods for using the polypeptides of the invention and fragmented peptides thereof as markers, which aid in the determination of the isoelectric point of a sample protein. The invention also encompasses methods for using polypeptides of the invention and fragmented peptides thereof as controls for establishing the extent of fragmentation of a protein sample.

10

Further encompassed by this invention are kits to aid the determination of molecular weights of a sample protein utilizing polypeptide molecular weight markers of the invention, fragmented peptides thereof, and forms of these polypeptide molecular weight markers, wherein at least one of the sites necessary for fragmentation by chemical or enzymatic means has been mutated.

15

20

#### DETAILED DESCRIPTION OF THE INVENTION

The protein kinases are a large family of enzymes, many of which mediate the response of eukaryotic cells to external stimuli. In recent years, members of the protein kinase family have been discovered at an accelerated pace. The surge in the number of known protein kinases has been largely due to the advent of gene cloning and sequencing techniques. Amino acid sequences deduced from nucleotide sequences are considered to represent protein kinases if they include certain key residues that are highly conserved in the protein kinase catalytic domain. A cDNA encoding a human polypeptide has been isolated and is set forth in SEQ ID NO:1, 2, 3, 4, 5, 6, 13, or 15. This discovery of the cDNA encoding human polypeptides having kinase functions enables construction of expression vectors comprising nucleic acid sequences encoding polypeptides having kinase functions; host cells transfected or transformed with the expression vectors; biologically active human polypeptides having kinase functions, and molecular weight markers as isolated and purified proteins; and antibodies immunoreactive with polypeptides of the invention.

More particularly, the invention relates to certain nucleotide sequences. A "nucleotide sequence" refers to a polynucleotide molecule in the form of a separate fragment or as a component of a larger nucleic acid construct, that has been derived from DNA or RNA isolated at least once in substantially pure form (i.e., free of contaminating endogenous materials) and in a quantity or concentration enabling identification, manipulation, and recovery of its component nucleotide sequences by standard biochemical methods (such as those outlined in Sambrook et al., *Molecular Cloning: A*

5

*Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989)). Such sequences are preferably provided and/or constructed in the form of an open reading frame uninterrupted by internal non-translated sequences, or introns, that are typically present in eukaryotic genes. Sequences of non-translated DNA can be present 5' 10 or 3' from an open reading frame, where the same do not interfere with manipulation or expression of the coding region.

10

5 Particularly preferred nucleotide sequences of the invention include the following:

15

**NAME: HH0900-BF04 DNA**

20 **10 Nucleotide sequence:**

GTACGCCATGAAGGTGCTGCCAAGGCCGCGCTGGTGCAGCGCGCCAAGA  
CGCAAGAGCACCGCGACCGAGCGCTCGGTCTGGAGCTGGTGCAGCGCCAAGA  
GCGCCCTTCCTGGTACGCTGCACTACGCTTCCAGACGGATGCCAAGCT  
GCACCTCATCCTGGACTATGTGAGCGGGGG (SEQ ID NO:1);

15

25 **NAME: HH2040-BF04 DNA**

**20 Nucleotide sequence:**

CCCGAGAGGTGCCACATCAGACCGCCTCCGACTTCGTGCGGGACTCGGCG  
GCCAGCCACCGCGGAGCCGAGGCCTGACAGCGGGCGTGTGCTTCCT  
GCTCTGCAACTCTGCAACGGGCTGGAGCACCTGAAGGAGCACGGGATCA  
30 TCCACCGGACCTGTGCCCTGGAGAACCTGCTGGTGCACCTGCACCCCTC  
CAGGCCGGCCCCGGGCCCC (SEQ ID NO:2);

35 **Name: JJ503-KS DNA**

25 **nucleotide sequence**

CGGGCAGGGCTGGAGCTGGGCTGGGATCCCGAGCTCGGCAGCGCGCAGCGGGCCGGCCACCTGCTGGTGC  
CCTGGAGGCTCTGAGCCCCGGCGGCCGGCCAGCGGAACGACGGGGGAGATGCGAGCCACCCCTCT  
GGCTCTCTGGGGTTCCCTGTCAGGAAGAGCGGTTGGACTTGGATGACAACCTAGATAACCGAGCGTCC  
CGTCCAGAAACGAGCTGAAGTGGGCCCCAGCCACTGCCCCCTGCTGTGCCCCCTGAGCCCCACCTAC  
40 TGCTCCAGATCTGCAACTGCTGTGGCCACTGCTCTCCGCTTGTGGCCCTATGTCTCTGGAGCCCAGGA  
GGGCGGGCGGGCCCTACCAAGGCCCTGCACTCCCTACAGGCACTGAGTAACCTGCAAGGTGTACCCCTCCA  
GGAAGCCCTGGCGTGTGGAGCCCTACGCGCGCTGCCCCCGACAAGCATGTGGCTGGCCACTGAGGT  
CCTGGCTGGTACCCAGCTCCCTACGCTTTCACTCGGACCCATGGGACATGCAAGCCCTGGTGGAG  
CCGCCACCGGTGGTCTGGCTGGCTGAGGCTGCGCTCTTCCCGAGATGCCACCCCTGGCCACTGTCA  
45 CCAGCACGGTCTGGTCTGGCTGAGTCTCAAGCTGTGCGCTTGTCTCGCTGACCGTGAGAGGAAGAGCT  
GGTCTGGAGAACCTGGAGGACTCTGCTGCTGACTGGGCAAGATGATTCCTGTGGGACAAGCACCGTG  
CCCAGCCTACGTGGGACCTGAGATACTCAGCTCACGGGCTCATACTCGGCAAGGCAGCGATGTGGAG  
50 CCTGGGCGTGGCGCTCTCACCATGCTGGCCGCAACTACCCCTCCAGGACTCGGAGCCGTGCTCTGG  
CGCAAGATCCGGCGGGGCTACGCCCTGCGCTGAGGCTCTCGGCCCCCTGCCCCGTGCTGGTTCGCTG  
40 CCTCTTCGTCGGAGCCAGCTGAACGGCTCACAGCCACAGGCATCCTCTGCACCCCTGGCTGCGACAGGA  
CCCGA (SEQ ID NO:3);

50

**Name: QQ1249-BF04 DNA**

10

**Nucleotide sequence:**

5 CAGCAGAGAAGCCGACATGCCATGCCCTTCAATCACCCAAACATCCTTCG  
 CCTCGGCTTACTGTCAGGGAACGGGGTGTAAAGCATGAGGCCCTGGC  
 TGCTGCTACCATCTTCAGAGAGGTACGCTGTGGAAATGAGATAGAAAGG  
 CTGAAGGACAAAGGAACTTCTGACCGAGGATCAAATCCTTGGCTGCT  
 GCTGGGGATCTGAGAGGCCATTGAGGCCATTGAGGCCATTGAGGCC  
 15 ACAGAGACTTGAAGCCCACCAATATATTGCTTGAGATGAGGGCAGCCA  
 GTTTAATGGACTGGGTTCCATGAATCAAGCATGCATCCATGTGGAGGG  
 10 CTCGGCCAGGCTCTGACCCCTGAGGACTGGCAGGCC (SEQ ID NO: 4);

15

**Name: QQ3351-BF04 DNA**

20

**Nucleotide sequence:**

15 ATGCTAACTAGTTAACAGACTTGGAACAGACGACCTGCTGTGGAAAGAGCGAGCTTTTGGAACTGTGC  
 ACGGGACAGATTGGACGACACCCCTCGGGAGGCCGAAGGCATGGAAAATTGAGCATATTACCCCT  
 GGCCAGGTACATCCACAAACGGCTGTGAAGAGATGAAATACTGCAAGAACAGTGCCTGGCGCCCTGGGCCACCGC  
 GTCTCGGCTGTACAGCCTGAGGATGCTCCAGGACAGGAGGCTGCCCCCTGAGAAGGTTA  
 25 ACCACAGCCATGAAGCGCTTCAAGGCTGCCCCCTGGAGGAGGCTAATGGGAGATAGAAAAGTTGAGCAATAGA  
 TCCAAATATCTGAGGTTTCTAACAGCAAGGCCAGGACAAATACTCTTCAGGACGTGAACAGGAAGTGAGT  
 GATGCTTGGAAAGGAGCTCGCTGTTACTTCAGGTTGAGCAACGCATGCCCTGTTTACCCATAAGCCAAGGA  
 GCGCTCTGGGACAGGAAGATCAGCAGGATGCAAGCAGCAGGAGCTTTCCAGATGCTAAGAAGAGAT  
 20 AATGAAAATAGAAGCTTCACTGAGAGATGAAATCAACATGAAAGAAATCAAGGAAACTTTGAGGCAG  
 TATTACCAACAAATGCACTGAGGAGATCCCCAAGACCAATCAAGGAGATCAAGAAGGAGCAGCTTCA  
 25 GGATCCCCGTGGATTCTGCTAAGGGAAATGAAGTCAGCACACTTATAAAGGAGAATACACAGAGCTCCA  
 GTGCCATAAAAGTATTCAAAAACCTCAGGCTGCAGCATGCAATAGTGAGGCAGACTTCAATAAGGAG  
 30 ATCAAAACCATGAAGAAATTGCAATCTCCACATCTCGCTATATTGGGATTTCATTGAAACACTG  
 ACTCCGCTCAATCTCCATGTCATGGAGTACTGTGAACCTGGGACCTGAGGGAGCTTGGATAGGGAA  
 AAAGACCTCACACTTGGCAAGGCATGGCTAGTCCCTGGGGCAGCCGAGGCCCTACACCAT  
 35 TCAGAAGCCTGAACCTCACGGAAAATCAAGAGCTCAAAACTCTGGTAACCTCAAGGCTACCAAGTGAAG  
 CTTGAGGATTGAGTTGAGGAAAACACAGACTGGCATGAGTTGGAAACTCAGAGAGAAAAGACAGACAGA  
 GTCAAATCTACACCATATCTCACCTCAGGAACCTGGAAATGTTATCAATATGATGAAAGTCTGAA  
 40 40 **Name: SS1771**  
**Nucleotide sequence:**

45 CTTCCCGCTG GACGTGGAGT ACGGAGGCC AGACCGGAGG TGCCCGCCTC  
 CGCCCTACCC GAAGCACCTG CTGCTGCGCA GCAAGTCGGA GCAGTACGAC  
 CTGGACAGCC TGTGCGCAGG CATGGAGCAG AGCCTCCCTG CGGGCCCCAA  
 CGAGCCCCGAG GGCGGCAGCA AGAGCCGCAAG AAGGCCAAG GGGGACAAAG  
 GCGGAAAGGA TAAAAGCAG ATTCAAGCTT CTCCCGTTC CGTCCGCAAA  
 AACAGCAGAG ACGAAGAGAA GAGAGACTCA CCCATCAAGA GCTACTGCC  
 ATACGCCCTT AAGTCTTCA TGGAGCAGCA CGTGGAGAAT GTCATCAAAA  
 50 CCTACCAGCA GAAGGTTAAC CGGAGGCTGC AGCTGGACCA AGAAATGGCC  
 AAAGCTGGAC TCTGTGAAGC TGAGCAGGAG CAGATGCGGA AGATCCTCTA  
 CCAGAAAGAG TCTAATTACA ACAGGTTAAA GAGGGCCAAG ATGGACAAGT  
 55 CTATGTTGT CAAGATCAA ACCCTGGGAA TCGGTGCCCTT TGGAGAAGT

5

5            TGCCTGCTT GTAAGGTGGA CACTCACGCC CTGTACGCCA TGAAGACCT  
 AAGGAAAAAG GATGTCCTGA ACCGGAATCA GGTGGCCAC CTCAAGGCCG  
 AGAGGGACAT CCTGGCCGAG CGACACAATG AGTGGGTGGT CAAACTCTAC  
 TACTCTTCC AAGACAAAGA CAGCTGTAC TTTGTGATGG ACTACATCCC  
 10            TGGTGGGAC ATGATGAGCC TGCTGATCCG GATGGAGGTC TTCCCTGAGC  
 ACCTGGCG GTTCTACATC GCAGAGCTGA CTTTGGCCAT TGAGAGTGT  
 CACAAGATGG GCTTCATCCA CCGAGACATC AAGCTGTATA ACATTTGAT  
 AGATCTGGAT GGTACATTA AACTCACAGA TTTCGGCTC TGCACTGGT  
 15            TCAGGTGGAC TCACAATTCC AAATATTACG AGAAAGGGAG CCATGTCAGA  
 CAGGACACCG CGAGCTGAG GATGATGTTG CTAACTGTCG  
 GTGTGGGAC AGGCTGAAGA CCCTAGAGCA GAGGGCGGG AAGCAGCACC  
 AGAGGTGCCCT GGCACATTC CTGGTGGGA CTCCAACATA CATCGCACCC  
 20            GAGGTGCTCC TCCGCAAAGG GTACACTCAA CTCTGTACT GGTGGACTGT  
 TGGAGTATT CTCTTCGAGA TGCTGGTGGG GCAGCCGCC TTTTGGCAC  
 25            20            (SEQ ID NO:6).

**Name: SS1771A**

25

**25            Nucleotide sequence:**

TCCCGCTGGACCTGGAGTACGGAGGCCAGACCCGGAGGTGCCCGCCCTCCGGCCCTACCCGAAGCACCTGCTGC  
 TGGCAGCAAGTGGAGCAGTACGACCTGGACAGCTGCGCAGGCACTGGAGCAGAGCTCCCTGCGGCC  
 CCAAGGAGCCGAGGGCGGCCACAAGAGGCCAAAAGGCCAAGGGGGACAAGGGGAAAGGATAAAAAGC  
 AGATTCAGACCTCTCCGGTCCGGCAGAAACACCCAGAGACAGAAGAGAGAGTCACCCATCAAGA  
 30            GCTACTCGCCATACGCCCTTAAGTTCTCATGGAGCAGCACGGAGAATGTCATCAAAACCTACCAGCAGA  
 AGGTTAACCGGAGGCTGAGCTGGAGCAAGAAATGGCAAAGCTGGACTCTGTGAAGCTGAGCAGGAGCAGA  
 TGGGAAGATCCTTACACAGAAAGACTAATTACACAGCTTAAAGAGGCCAAGATGGACAAGTCTATGT  
 TTGTCAGATCAAACCCCTGGGATCGGGCTGGAGAATGCTGCTCTTGTAAAGGTGGACACTCAG  
 35            CCTCTACGCCATGAAAGCCCTAAGGAAAAGGATGTCATGAAACCCCTACTACTCCAAAGACAAAGACA  
 AGAGGGACATCTGGCCAGGCAGACAATGAGTGGGTGCTCAAACCTACTACTCCAAAGACAAAGACA  
 GCCCTGACTTTGTGATGGACTACATCCCTGCTGGGACATGATGAGCCTGATCGGATGGAGGTCTTC  
 CTGAGCACCTGGCCCTCTACATCGCAGACTGACTTTGGCCATTGAGCTTGGCCACAAAGATGGCTCA  
 TCCACCGAGACATCAAGCCGTATAACATTGATAGATCTGGATGGTCACATTAACCTCACAGATTTCGCC  
 40            TCTGCACTGGGTTCAAGGTGGACTCACAAATTCCAATTACCAAGAAAGGGGCCATGTCAGCAGGACAGCA  
 TGGGCCCAGGCCCTCTGGGATGATGTGTCCTACTGCGGTGAGGGACGGCTGAAGACCCCTAGAGCAGA  
 GGGCGCGGAAAGCAGCAGGAGGTGCGCAGCTAACATTACTGGGACTCTCAACATCCACCCGAGG  
 TGCTCTCCGCAAGGGTACACTCAACTCTGACTGCTGGAGTGTGGAGTGTCTCTGAGATGCTGG  
 TGGGGCAGGCCCTTTGGCACCTACTCCACAGAAACCCAGCTGAAGGTGATCAACTGGAGAACACGC  
 45            TCCACATTCCAGGCCAGGTGAAGCTGAGCCCTGAGGCCAGGGACCTCATACCAAGCTGCTGCTCCGAG  
 ACCACCGCCCTGGGGCAATGGGCCGATGACTGAGGCCACCCCTCTCAGGGCCATTGACTTCTCCA  
 GTGACATCCGGAAGCATCCAGGCCCTACGTCCCCACCATCAGGCCACCCATGGACACCTCGAATTTCGACC  
 50            CCGTAGATGAAGAAAGCCCTTGAACGATGCCAGCAAGGTAGCACCAAGGCCCTGGGACACACTCACCTCGC  
 CCAATAACAAACCATCCCTGAGCACCCATTTCAGAATTCACTTCCGAGGTCTTTGATGACAATGGCTTAC  
 CCTTCGATGCCAAAGCCTCAGGAGCAGAGCTTCAGGCTGAGAGCTCAGAGTTAGAAAAGCTGATC  
 TGGTGGATCACTGAGCTGGCCAGGCTGTGAGTGGGGCAGGCACCCCCAACACTCGCTGC  
 CTCCCAAGGTAGGGTCCGGAGCCGGTGCCTCACAGGCCAATAGGGAAAGCCGAGGGCTGTGTTGTTTAAA  
 TTAGTCCGTCGATTAACCTCACTGAAATTCTGCTCTCACCAAGAAAACCCAAACAGGACACTTTGAAAC  
 AGGGTGGCGCAATT (SEQ ID NO:15).

45

55

55            With the continued increase in the number of known eukaryotic protein kinases, a suitable classification scheme is one based on comparing catalytic-domain sequences. It follows that protein kinases with similar catalytic domains will tend also to have similar

50

5

enzymatic and regulatory properties. The nucleotide sequences of the invention encode, respectively, the following polypeptides having kinase function:

10

**NAME: HH0900-BF04 Polypeptide**

5 **Translation in relevant reading frame (3'-5' Frame 3):**

YAMKVLRKAALVQRAKTQEHTRTERSVLELVRQAPFLVTLHYAFQTDALKHLILDY  
15 VSGG (SEQ ID NO:7);

10 The above sequence is consistent with the consensus sequence of subdomains II through V of the eukaryotic protein kinase superfamily. This sequence is the sequence of a 20 polypeptide having kinase activity encoded by the nucleotide sequence of SEQ ID NO:1.

20

**NAME: HH2040-BF04 Polypeptide**

15

25 **Translation in relevant reading frame (5'-3' Frame 2):**

REVPHQTASDFVRDSAASHQAEPEAYERRVCFLQLCNGLE  
HLKEHGIIRHDLCLENLLLHVCTLQAGPGPA (SEQ ID NO:8);

30

20 The above sequence is consistent with the consensus sequence of subdomains V, VIA and VIB of the eukaryotic protein kinase superfamily. This sequence is the sequence of a 35 polypeptide having kinase activity encoded by the nucleotide sequence of SEQ ID NO:2.

35

25 **Name: JJ503-KS Polypeptide**

40 **Translation in relevant reading frame (5'-3' frame 1):**

40 GOGWSWAGIPSSAAAQRAGPPAGALEALSPGGARAHAEERRGEMRATPLAA  
PAGSLSRKKRLELDDNLDTERPVQKRARSGPQPRLLPPCLLFLSPPTAPDR  
30 ATAVATASRLGPYVLLPEPEEGGRAYQALHCPPTGTEYTCVKVVPVQEALAVL  
EPYARLPPHKHVARPTEVLAGTOLLYAFFTRTHGDMHSLVRSRHRIPPEPE  
AAVLFRQMATALAHCHQHGLVRLDLKLCRFVFAADRERKKLVLENLEDSCV  
45 LTGPDDDSLWDKHACPAYVGPEILSSRSASYSGKAADVWSLGVALFTMLAGH  
YPFQDSEPVLLFGKIRRGAYALPAGLSAPARCLVRCLLRREPAERLTATG  
35 ILLHPWLRQD (SEQ ID NO:9);

50

5

The sequence is consistent with kinase domains VIA through XI, though the homology is imperfect. This sequence is the sequence of a polypeptide having kinase activity encoded by the nucleotide sequence of SEQ ID NO:3.

10

5 Name: QQ1249-BF04 Polypeptide

Translation in relevant reading frame (5'-3' frame 3)

15

10 QREADMHRLFNHPNILRLVAYCLRERGAKHEAWLLLPPFKRGTLLWNEIER  
LKDKGNFLTEDQILWLLLGICRGLEATHAKGYAYRDLKPTNILLGDEGQP  
VLMDLGSMNQACIHVEGSRQALTLQDWAAQRCTISYRAPXLFSVQS  
(SEQ ID NO:10);

20

15 The above sequence is consistent with the consensus sequence of subdomains III - VIII of the eukaryotic protein kinase superfamily. This sequence is the sequence of a polypeptide having kinase activity encoded by the nucleotide sequence of SEQ ID NO:4.

25

Name: QQ3351-BF04 Polypeptide

Translation in relevant frame (5'-3' frame 1)

30

20 MLTSLNRSWNETTCCGRASFLELC TGQ1GRTPLGRREGMENLKHIITLGQVIHKRCEEMKYCKQCRRLLGHR  
VLGLIKPLEMLQDGKRSVPSEKLTTAMNRKKALEEANGIEIEKFNSRNSNICRFLTASQDKILFKDVNRKLS  
DWKELSLLLQVEQRMFVSPISQGASWAQEDQQDADEDRRAFQMLRRDNEKIEASLRRLEINMKEIKETLRQ  
YLPPKCMQEIPQEIQUEIKKEQLSGSPWILLRENEVSTLYKGEYHRAPVAIKVFKKLQAGSIAIVRQTFNKE  
25 IKTMKKFESPNILRIFGICIDETVTPQFSIVMEYCELGTLRELLDREKDIDLGKRMVLVVLGAARGLYRLHH  
SEAPELHGKIRSSNLFVLTQGYQVKLAGFELRKTQTSMSLGGTREKTDRVKSTAYLSPQELEDVFYQYDVKSE  
IYSGFIVLWEIATGDIPLFQGCNSEKIRKLVAVKRQQEPLGEDCPSELREIIDECRAAGRLVPRSVAAARAVD  
v (SEQ ID NO:11)

35

30 The above sequence is believed to be full-length. However, the initial methionine was not present in the clone sequenced but subsequently was added by PCR. Therefore, the natural sequence may comprise Leu-2 through the Val-505. This sequence is the sequence of a polypeptide having kinase activity encoded by the nucleotide sequence of SEQ ID NO:5.

40

35

Name: SS1771

45

Translation in relevant frame (3'-5' frame 3)

50

40 FPLDVEYGGPDRRCPPPPYPKHLLRSKSEQYDLDSCAGMEQSLRAGPN  
EPEGGDKSRKSAGDKGGDKKQIQTSPVPRKNSRDEEKRESRIKSYS  
YAFKFFMEQHVENVNIKTYQQKVNRRQLQEQA  
KAGLCEAEQEQM  
RKESNYNRLKRAKMDKSMFVKIKTLGIGAFGEVCLACKVDT  
THALYAMKTL  
RKKDVLNRNQVAHVKAERDILAEADNEWVVKLYYSFQDKDSL  
YFVMDY1P

5

GGDMMSSLIRMEVFPEHLARFYIAELTLAIESVHKMGIHRSRDKPDNILLI  
 DLDGHIKLTDGLCTGFRWTHNSKYYQKGSHVRQDSMEPSDLWDDVSNCR  
 CGDRLKTLERQRKQHQRCLAHSLVGTNPYIAPEVLLRKGYTQLCDWWSV  
 GVILFEMILVGQPPFLAPTPTEQLKVINWENTLHIPAQPVQLSPEARDLIT  
 KLCCSADHRLGRNGADDLKAHPFFSAIDFSSDIRKHPAPYVPTISHPME  
 (SEQ ID NO:12).

10

This sequence is the sequence of a polypeptide having kinase activity encoded by the nucleotide sequence of SEQ ID NO:6. The sequence may also comprise Pro-2 through Glu-499.

15

**Name: SS1771A**

**Translation in relevant frame (5'-3' frame 3)**

20

PLDVEYGGPDRCPPPPYPKHLLRSKSEQYDLDLSCAGMEQSLRAGPNEPEGGDKSRKSAKGDKGGDKKQ  
 IOTS PVPVRKNSRDEEKRESRIKSYPYAFKFMEQHVENVIKTYQQKVNRRLQLEQEMA KAGLCEAEQEQM  
 RKILYQKESNYNRKRAKMDKSMFVKIKTLGIGAFGEVCLACKVDTHALYAMKTLRKKDVLNRNQVAHVKA  
 RDILAEADNEVVVKLYYSFQDKDSLIFVMDYI PGGDMMSSLIRMEVFPEHLARFYIAELTLAIESVHKMGI  
 HRDIKPDNILLIDLDGHIKLTDGLCTGFRWTHNSKYYQKGSHVRQDSMEPSDLWDDVSNCRCGDRLKTLER  
 25 20 ARKQHQRCLAHSLVGTNPYIAPEVLLRKGYTQLCDWWSGVUILFEMILVGQPPFLAPTPTEQLKVINWENTL  
 HIPAQPVQLSPEARDLITKLCCSADHRLGRNGADDLKAHPFFSAIDFSSDIRKHPAPYVPTISHPMDTSNFDP  
 VDEESPWNDASEGSTKAWDTLSPNNKHPEHAFY EFTFRFFDDNGYPFRCPKPSGAEASQAESSDLESSDL  
 VDQTEGCQPVV (SEQ ID NO:16)

25 This sequence is the sequence of a polypeptide having kinase activity encoded by the nucleotide sequence of SEQ ID NO:1.

30

The invention also includes truncated forms of the nucleic acids and polypeptides of the invention. In a preferred embodiment, the invention includes a truncated form of QQ3351-BF04, as follows:

35

30 **Nucleotide sequence:**

CTTCAGGATTGAGTTGAGAAAACACAGACTTCCATGAGTTGGAACTACGAGAGAAAAGACAGACAGA  
 GTCAAATCTACAGCATATCTCACCTCAGGAACCTGGAAATGTATTATCAATATGATGTAAAGTCTGAA  
 40 35 ATATACAGTTGAAATCGTCCCTGGAAATCGCCACTGGAGATATCCGTTCAAGGCTGTAATTCTGAG  
 AAGATCCGCAAGCTGGTGGCTGTGAAGCGGCAGCAGGAGCCACTGGTGAAGACTGCCCTCAAGAGCTGGG  
 GAGATCATTGATGAGTGGCGGGCCATGATCCCTCTGTGCGGCCCTGTGGATGAAATCTAAAGAAACTC  
 TCCACCTTTCTAAG (SEQ ID NO:13)

40 **Translation in relevant frame (5'3' frame 1):**

45

LAGFELRKQTMSLGLTREKTDVKSTAYLSPQELEDVYQYDVKSEIYS  
 FGIVLWEIATGDI PFGCNSEKIRKLVAVKRQQEPLGEDCPSELREI IDEC  
 RAHDPSVRPSVDEILKKLSTFSK (SEQ ID NO:14)

45

This sequence is the sequence of a polypeptide having kinase activity encoded by the nucleotide sequence of SEQ ID NO:13.

50

5

The polypeptides of the invention are useful for characterizing cell and tissue expression, understanding their roles in development or hormonal response, and identifying regulatory molecules and physiologically relevant protein substrates.

10

As used herein, the term "polypeptides of the invention" refers to a genus of

15

polypeptides that further encompasses proteins having the amino acid sequence of SEQ ID NO: 7, 8, 9, 10, 11, 12, 14, or 16 as well as those proteins having a high degree of similarity (at least 90% homology) with such amino acid sequences and which proteins are biologically active. In addition, polypeptides of the invention refers to the gene products of the nucleotides of SEQ ID NO:1, 2, 3, 4, 5, 6, 13 or 15.

20

10 The isolated and purified polypeptides of the invention have molecular weights of approximately 6883 (HH0900-BF04); 8168 (HH2040-BF04); 39,284 (JJ503-KS); 16,718 (QQ1249-BF04); 58,001 (QQ3351-BF04); 57,381 (SS1771), and 67,331 (SS1771A) Daltons in the absence of glycosylation. It is understood that the molecular weight of these polypeptides can be varied by fusing additional peptide sequences to both the amino and carboxyl terminal ends of polypeptides of the invention. Fusions of additional peptide sequences at the amino and carboxyl terminal ends of polypeptides of the invention can be used to enhance expression of these polypeptides or aid in the purification of the protein.

25

30 It is understood that fusions of additional peptide sequences at the amino and carboxyl terminal ends of polypeptides of the invention will alter some, but usually not all, of the fragmented peptides of the polypeptides generated by enzymatic or chemical treatment.

35

35 It is understood that mutations can be introduced into polypeptides of the invention using routine and known techniques of molecular biology. It is further 40 understood that a mutation can be designed so as to eliminate a site of proteolytic cleavage by a specific enzyme or a site of cleavage by a specific chemically induced fragmentation procedure. It is also understood that the elimination of the site will alter the peptide fingerprint of polypeptides of the invention upon fragmentation with the specific enzyme or chemical procedure.

45

45 The term "isolated and purified" as used herein, means that the polypeptides or fragments of the invention are essentially free of association with other proteins or polypeptides, for example, as a purification product of recombinant host cell culture or as a purified product from a non-recombinant source. The term "substantially purified" as used herein, refers to a mixture that contains polypeptides or fragments of the invention

50

5

and is essentially free of association with other proteins or polypeptides, but for the presence of known proteins that can be removed using a specific antibody, and which substantially purified polypeptides or fragments thereof can be used as molecular weight markers. The term "purified" refers to either the "isolated and purified" form of polypeptides of the invention or the "substantially purified" form of polypeptides of the invention, as both are described herein.

10

5

A polypeptide "variant" as referred to herein means a polypeptide substantially homologous to native polypeptides of the invention, but which has an amino acid

15

sequence different from that of native polypeptides (human, murine or other mammalian species) of the invention because of one or more deletions, insertions or substitutions.

20

10 The variant amino acid sequence preferably is at least 80% identical to a native

polypeptide amino acid sequence, most preferably at least 90% identical. The percent

identity can be determined, for example, by comparing sequence information using the

GAP computer program, version 6.0 described by Devereux et al. (*Nucl. Acids Res.*

25

15 12:387, 1984) and available from the University of Wisconsin Genetics Computer Group

(UWGCG). The GAP program utilizes the alignment method of Needleman and Wunsch

(*J. Mol. Biol.* 48:443, 1970), as revised by Smith and Waterman (*Adv. Appl. Math* 2:482,

1981). The preferred default parameters for the GAP program include: (1) a unary

30

comparison matrix (containing a value of 1 for identities and 0 for non-identities) for

20 nucleotides, and the weighted comparison matrix of Gribskov and Burgess, *Nucl. Acids*

*Res.* 14:6745, 1986, as described by Schwartz and Dayhoff, eds., *Atlas of Protein*

*Sequence and Structure*, National Biomedical Research Foundation, pp. 353-358, 1979;

35 (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each

gap; and (3) no penalty for end gaps.

25 Variants can comprise conservatively substituted sequences, meaning that a given

amino acid residue is replaced by a residue having similar physiochemical characteristics.

40 Examples of conservative substitutions include substitution of one aliphatic residue for

another, such as Ile, Val, Leu, or Ala for one another, or substitutions of one polar residue

for another, such as between Lys and Arg; Glu and Asp; or Gln and Asn. Other such

45 30 conservative substitutions, for example, substitutions of entire regions having similar

hydrophobicity characteristics, are well known. Naturally occurring variants are also

encompassed by the invention. Examples of such variants are proteins that result from

50 alternate mRNA splicing events, proteolytic cleavage of the polypeptides, or

transcription/translation from different alleles. Variations attributable to proteolysis

5

include, for example, differences in the N- or C-termini upon expression in different types of host cells, due to proteolytic removal of one or more terminal amino acids from the polypeptides (generally from 1-5 terminal amino acids) of the invention.

10

The polypeptides of the invention can also exist as oligomers, such as covalently linked or non-covalently linked dimers or trimers. Oligomers can be linked by disulfide bonds formed between cysteine residues on different polypeptides.

15

In one embodiment of the invention, a polypeptide dimer is created by fusing polypeptides of the invention to the Fc region of an antibody (e.g., IgG1) in a manner that does not interfere with the biological activity of these polypeptides. The Fc region

20

preferably is fused to the C-terminus of a soluble polypeptide of the invention, to form an Fc fusion or an Fc polypeptide. The terms "Fc fusion protein" or "Fc polypeptides" as used herein includes native and mutein forms, as well as truncated Fc polypeptides containing the hinge region that promotes dimerization. Exemplary methods of making Fc polypeptides set forth above are disclosed in U.S. Patents 5,426,048 and 5,783,672

25

both of which are incorporated herein by reference.

30

In a preferred embodiment, extracellular domains from transmembrane bound kinases are fused to Fc portions of antibodies to produce soluble Fc polypeptides. These constructs can function as binding sites for the ligand that naturally binds the kinase receptor and thereby inhibit binding of the ligand to the natural receptor.

35

General preparation of fusion proteins comprising heterologous polypeptides fused to various portions of antibody-derived polypeptides (including the Fc domain) has been described, e.g., by Ashkenazi et al. (*PNAS USA* 88:10535, 1991) and Byrn et al.

40

(*Nature* 344:677, 1990), hereby incorporated by reference. A gene fusion encoding the polypeptide:Fc fusion protein of the invention is inserted into an appropriate expression vector. Polypeptide:Fc fusion proteins are allowed to assemble much like antibody molecules, whereupon interchain disulfide bonds form between Fc polypeptides, yielding divalent polypeptides of the invention. If fusion proteins are made with both heavy and light chains of an antibody, it is possible to form a polypeptide oligomer with as many as four polypeptides extracellular regions. Alternatively, one can link two soluble

45

polypeptide domains with a peptide linker.

50

In one embodiment of this invention, the polypeptides of the invention are produced by recombinant expression. In one preferred embodiment, the expression of recombinant polypeptides having kinase functions can be accomplished utilizing fusion of sequences encoding polypeptides having kinase functions to sequences encoding another

5

polypeptide to aid in the purification of polypeptides of the invention. An example of such a fusion is a fusion of sequences encoding a polypeptide having kinase functions to sequences encoding the product of the *malE* gene of the pMAL-c2 vector of New England Biolabs, Inc. Such a fusion allows for affinity purification of the fusion protein, as well as separation of the maltose binding protein portion of the fusion protein from the polypeptide of the invention after purification.

10

15

The insertion of DNA encoding the polypeptide having kinase functions into the pMAL-c2 vector can be accomplished in a variety of ways using known molecular biology techniques. The preferred construction of the insertion contains a termination codon adjoining the carboxyl terminal codon of the polypeptide of the invention. In addition, the preferred construction of the insertion results in the fusion of the amino terminus of the polypeptide of the invention directly to the carboxyl terminus of the Factor Xa cleavage site in the pMAL-c2 vector. A DNA fragment can be generated by PCR using DNA of the invention as the template DNA and two oligonucleotide primers.

20

10 Use of the oligonucleotide primers generates a blunt-ended fragment of DNA that can be isolated by conventional means. This PCR product can be ligated together with pMAL-p2 (digested with the restriction endonuclease *Xmn* I) using conventional means. Positive clones can be identified by conventional means. Induction of expression and purification of the fusion protein can be performed as per the manufacturer's instructions. This 15 construction facilitates a precise separation of the polypeptide of the invention from the fused maltose binding protein utilizing a simple protease treatment as per the manufacturer's instructions. In this manner, purified polypeptide having kinase functions can be obtained. Furthermore, such a constructed vector can be easily modified using 20 known molecular biology techniques to generate additional fusion proteins. It is 25 understood, of course, that many different vectors and techniques can be used for the 30 expression and purification of polypeptides of the invention and that this embodiment in 35 no way limits the scope of the invention.

40

40 Polypeptides of the invention can be subjected to fragmentation into peptides by 45 chemical and enzymatic means. Chemical fragmentation includes the use of cyanogen bromide to cleave under neutral or acidic conditions such that specific cleavage occurs at 50 methionine residues (E. Gross, *Methods in Enz.* 11:238-255, 1967). This can further include additional steps, such as a carboxymethylation step to convert cysteine residues to an unreactive species. Enzymatic fragmentation includes the use of a protease such as Asparaginylendopeptidase, Arginylendo-peptidase, *Achromobacter* protease I, Trypsin,

5

*Staphlococcus aureus* V8 protease, Endoproteinase Asp-N, or Endoproteinase Lys-C under conventional conditions to result in cleavage at specific amino acid residues. Asparaginylendo-peptidase can cleave specifically on the carboxyl side of the asparagine residues present within the polypeptides of the invention. Arginylendo-peptidase can cleave specifically on the carboxyl side of the arginine residues present within these polypeptides. *Achromobacter* protease I can cleave specifically on the carboxyl side of the lysine residues present within the polypeptides (Sakiyama and Nakat, U.S. Patent No. 5,248,599; T. Masaki et al., *Biochim. Biophys. Acta* 660:44-50, 1981; T. Masaki et al., *Biochim. Biophys. Acta* 660:51-55, 1981). Trypsin can cleave specifically on the carboxyl side of the arginine and lysine residues present within polypeptides of the invention. *Staphlococcus aureus* V8 protease can cleave specifically on the carboxyl side of the aspartic and glutamic acid residues present within polypeptides (D. W. Cleveland, *J. Biol. Chem.* 3:1102-1106, 1977). Endoproteinase Asp-N can cleave specifically on the amino side of the asparagine residues present within polypeptides. Endoproteinase Lys-C can cleave specifically on the carboxyl side of the lysine residues present within polypeptides of the invention. Other enzymatic and chemical treatments can likewise be used to specifically fragment these polypeptides into a unique set of specific peptide molecular weight markers.

30

The resultant fragmented peptides can be analyzed by methods including sedimentation, electrophoresis, chromatography, and mass spectrometry. The fragmented peptides derived from the polypeptides of the invention can serve as molecular weight markers using such analysis techniques to assist in the determination of the molecular weight of a sample protein. Such a molecular weight determination assists in the identification of the sample protein. Fragmented peptide molecular weight markers of the invention are preferably at least 10 amino acids in size. More preferably, these fragmented peptide molecular weight markers are between 10 and 100 amino acids in size. Even more preferable are fragmented peptide molecular weight markers between 10 and 50 amino acids in size and especially between 10 and 35 amino acids in size. Most preferable are fragmented peptide molecular weight markers between 10 and 20 amino acids in size.

40

Furthermore, analysis of the progressive fragmentation of the polypeptides of the invention into specific peptides (D. W. Cleveland et al., *J. Biol. Chem.* 252:1102-1106, 1977), such as by altering the time or temperature of the fragmentation reaction, can be used as a control for the extent of cleavage of a sample protein. For example, cleavage of

45

55

5

the same amount of polypeptide and sample protein under identical conditions can allow for a direct comparison of the extent of fragmentation. Conditions that result in the complete fragmentation of the polypeptide can also result in complete fragmentation of the sample protein.

10

5 In addition, the polypeptides and fragmented peptides of the invention possess unique charge characteristics and, therefore, can serve as specific markers to assist in the determination of the isoelectric point of a sample protein or fragmented peptide using techniques such as isoelectric focusing. The technique of isoelectric focusing can be further combined with other techniques such as gel electrophoresis to simultaneously 15 separate a protein on the basis of molecular weight and charge. An example of such a combination is that of two-dimensional electrophoresis (T.D. Brock and M.T. Madigan, 20 *Biology of Microorganisms* 76-77 (Prentice Hall, 6d ed. 1991)). These polypeptides and fragmented peptides thereof can be used in such analyses as markers to assist in the determination of both the isoelectric point and molecular weight of a sample protein or 25 fragmented peptide.

20

Kits to aid in the determination of apparent molecular weight and isoelectric point 30 of a sample protein can be assembled from the polypeptides and peptide fragments of the invention. Kits also serve to assess the degree of fragmentation of a sample protein. The constituents of such kits can be varied, but typically contain the polypeptide and 35 fragmented peptide molecular weight markers. Also, such kits can contain the polypeptides wherein a site necessary for fragmentation has been removed. Furthermore, the kits can contain reagents for the specific cleavage of the polypeptide and the sample protein by chemical or enzymatic cleavage. Kits can further contain antibodies directed against polypeptides or fragments thereof of the invention.

40

25 The isolated and purified polypeptides of the invention have molecular weights of approximately 6883 (HH0900-BF04); 8168 (HH2040-BF04); 39,284 (JJ503-KS); 16,718 (QQ1249-BF04); 58,001 (QQ3351-BF04); 57,381 (SS1771), and 67,331 (SS1771A) 45 Daltons in the absence of glycosylation. The polypeptide of the invention, together with a sample protein, can be resolved by denaturing polyacrylamide gel electrophoresis by 50 conventional means (U. K. Laemmli, *Nature* 227:680-685, 1970) in two separate lanes of a gel containing sodium dodecyl sulfate and a concentration of acrylamide between 6-20%. Proteins on the gel can be visualized using a conventional staining procedure. The polypeptide molecular weight markers of the invention can be used as molecular weight marker in the estimation of the apparent molecular weight of the sample protein. The

5

unique amino acid sequence of SEQ ID NO:7, 8, 9, 10, 11, 12, and 16 correspond to molecular weight of approximately 6883; 8168; 39,284; 16,718; 58,001; 57,381; or 67,331 Daltons, respectively. Therefore, the polypeptide molecular weight markers serve

10

particularly well as a molecular weight marker for the estimation of the apparent molecular weight of sample proteins that have apparent molecular weights close to 6883; 8168; 39,284; 16,718; 58,001; 57,381; or 67,331 Daltons. The use of these polypeptide molecular weight markers allows increased accuracy in the determination of apparent molecular weight of proteins that have apparent molecular weights close to 6883; 8168; 39,284; 16,718; 28,982; or 57,381 Daltons. It is understood of course that many different techniques can be used for the determination of the molecular weight of a sample protein using polypeptides of the invention, and that this embodiment in no way limits the scope of the invention.

15

Another preferred embodiment of the invention is the use of polypeptides and fragmented peptides of the invention as molecular weight markers to estimate the

20

apparent molecular weight of a sample protein by gel electrophoresis. These fragmented peptides can be generated methods well known in the art such as chemical fragmentation. Isolated and purified polypeptides of the invention can be treated with cyanogen bromide under conventional conditions that result in fragmentation of the polypeptide molecular weight marker by specific hydrolysis on the carboxyl side of the methionine residues

30

25

within the polypeptides of the invention (E. Gross, *Methods in Enz.* 11:238-255, 1967). Due to the unique amino acid sequence of the polypeptides of the invention, the fragmentation of polypeptide molecular weight markers with cyanogen bromide generates a unique set of fragmented peptide molecular weight markers. The distribution of methionine residues determines the number of amino acids in each peptide and the unique

35

25

amino acid composition of each peptide determines its molecular weight. Polypeptide molecular weight markers of the invention can be analyzed by methods including sedimentation, gel electrophoresis, chromatography, and mass spectrometry.

40

The fragmented peptide molecular weight markers of the invention, together with a sample protein, can be resolved by denaturing polyacrylamide gel electrophoresis by

45

30

conventional means in two separate lanes of a gel containing sodium dodecyl sulfate and a concentration of acrylamide between 10-20%. Proteins on the gel can be visualized using a conventional staining procedure. The fragmented peptide molecular weight markers of the invention can be used as molecular weight markers in the estimation of the apparent molecular weight of the sample protein. The unique amino acid sequence of

50

55

5

each marker specifies a molecular weight. Therefore, the fragmented peptide molecular weight markers serve particularly well as molecular weight markers for the estimation of the apparent molecular weight of sample proteins that have similar apparent molecular weights. Consequently, the use of these fragmented peptide molecular weight markers 10 allows increased accuracy in the determination of apparent molecular weight of proteins.

10

Polypeptides on the membrane can be visualized using two different methods that allow a discrimination between the sample protein and the molecular weight markers.

15

Polypeptide or fragmented peptide molecular weight markers of the invention can be

visualized using antibodies generated against these markers and conventional

20

10 immunoblotting techniques. This detection is performed under conventional conditions that do not result in the detection of the sample protein. It is understood that it may not be possible to generate antibodies against all polypeptide fragments of the invention, since small peptides may not contain immunogenic epitopes. It is further understood that not 20 all antibodies will work in this assay; however, those antibodies which are able to bind

25

15 polypeptides and fragments of the invention can be readily determined using conventional techniques.

The sample protein is visualized using a conventional staining procedure. The molar excess of sample protein to polypeptide or fragmented peptide molecular weight markers of the invention is such that the conventional staining procedure predominantly

30

20 detects the sample protein. The level of these polypeptide or fragmented peptide molecular weight markers is such as to allow little or no detection of these markers by the conventional staining method. The preferred molar excess of sample protein to

35

polypeptide molecular weight markers of the invention is between 2 and 100,000 fold.

More preferably, the preferred molar excess of sample protein to these polypeptide

25 molecular weight markers is between 10 and 10,000 fold and especially between 100 and 1,000 fold.

40

The polypeptide or fragmented peptide molecular weight markers of the invention can be used as molecular weight and isoelectric point markers in the estimation of the apparent molecular weight and isoelectric point of the sample protein. These polypeptide

45

30 or fragmented peptide molecular weight markers serve particularly well as molecular weight and isoelectric point markers for the estimation of apparent molecular weights and isoelectric points of sample proteins that have apparent molecular weights and isoelectric points close to that of the polypeptide or fragmented peptide molecular weight markers of the invention. The ability to simultaneously resolve these polypeptide or fragmented

5

peptide molecular weight markers and the sample protein under identical conditions allows for increased accuracy in the determination of the apparent molecular weight and isoelectric point of the sample protein. This is of particular interest in techniques, such as two dimensional electrophoresis, where the nature of the procedure dictates that any markers should be resolved simultaneously with the sample protein.

10

In another embodiment, polypeptide or fragmented peptide molecular weight markers of the invention can be used as molecular weight and isoelectric point markers in the estimation of the apparent molecular weight and isoelectric point of fragmented peptides derived by treatment of a sample protein with a cleavage agent. It is understood of course that many techniques can be used for the determination of molecular weight and isoelectric point of a sample protein and fragmented peptides thereof using these polypeptide molecular weight markers and peptide fragments thereof and that this embodiment in no way limits the scope of the invention.

15

Polypeptide molecular weight markers encompassed by invention can have variable molecular weights, depending upon the host cell in which they are expressed. Glycosylation of polypeptide molecular weight markers and peptide fragments of the invention in various cell types can result in variations of the molecular weight of these markers, depending upon the extent of modification. The size of these polypeptide molecular weight markers can be most heterogeneous with fragments of polypeptide derived from the extracellular portion of the polypeptide. Consistent molecular weight markers can be obtained by using polypeptides derived entirely from the transmembrane and cytoplasmic regions, pretreating with N-glycanase to remove glycosylation, or expressing the polypeptides in bacterial hosts.

20

As stated above, the invention provides isolated and purified polypeptides, both recombinant and non-recombinant. Variants and derivatives of native polypeptides can be obtained by mutations of nucleotide sequences coding for native polypeptides. Alterations of the native amino acid sequence can be accomplished by any of a number of conventional methods. Mutations can be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling

30

ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion.

35

Alternatively, oligonucleotide-directed site-specific mutagenesis procedures can be employed to provide an altered gene wherein predetermined codons can be altered by

40

45

50

5

substitution, deletion or insertion. Exemplary methods of making the alterations set forth above are disclosed by Walder et al. (*Gene* 42:133, 1986); Bauer et al. (*Gene* 37:73, 1985); Craik (*BioTechniques*, January 1985, 12-19); Smith et al. (*Genetic Engineering: Principles and Methods*, Plenum Press, 1981); Kunkel (*Proc. Natl. Acad. Sci. USA* 82:488, 1985); Kunkel et al. (*Methods in Enzymol.* 154:367, 1987); and U.S. Patent Nos. 4,518,584 and 4,737,462, all of which are incorporated by reference.

10

Polypeptides of the invention can be modified to create polypeptide derivatives by forming covalent or aggregative conjugates with other chemical moieties, such as glycosyl groups, polyethylene glycol (PEG) groups, lipids, phosphate, acetyl groups and the like. Covalent derivatives of polypeptides of the invention can be prepared by linking the chemical moieties to functional groups on polypeptide amino acid side chains or at the N-terminus or C-terminus of a polypeptide of the invention or the extracellular domain thereof. Other derivatives of polypeptides within the scope of this invention include covalent or aggregative conjugates of these polypeptides or peptide fragments with other proteins or polypeptides, such as by synthesis in recombinant culture as N-terminal or C-terminal fusions. For example, the conjugate can comprise a signal or leader polypeptide sequence (e.g. the  $\alpha$ -factor leader of *Saccharomyces*) at the N-terminus of a polypeptide of the invention. The signal or leader peptide co-translationally or post-translationally directs transfer of the conjugate from its site of synthesis to a site inside or outside of the cell membrane or cell wall.

15

20

25

30

35

40

50

Polypeptide conjugates can comprise peptides added to facilitate purification and identification of polypeptides of the invention. Such peptides include, for example, poly-His or the antigenic identification peptides described in U.S. Patent No. 5,011,912 and in Hopp et al., *Bio/Technology* 6:1204, 1988.

The invention further includes polypeptides of the invention with or without associated native-pattern glycosylation. Polypeptides expressed in yeast or mammalian expression systems (e.g., COS-1 or COS-7 cells) can be similar to or significantly different from a native polypeptide in molecular weight and glycosylation pattern, depending upon the choice of expression system. Expression of polypeptides of the invention in bacterial expression systems, such as *E. coli*, provides non-glycosylated molecules. Glycosyl groups can be removed through conventional methods, in particular those utilizing glycopeptidase. In general, glycosylated polypeptides of the invention can be incubated with a molar excess of glycopeptidase (Boehringer Mannheim).

5

Correspondingly, equivalent DNA constructs that encode various additions or substitutions of amino acid residues or sequences, or deletions of terminal or internal residues or sequences are encompassed by the invention. For example, N-glycosylation sites in the polypeptide extracellular domain can be modified to preclude glycosylation, allowing expression of a reduced carbohydrate analog in mammalian and yeast expression systems. N-glycosylation sites in eukaryotic polypeptides are characterized by an amino acid triplet Asn-X-Y, wherein X is any amino acid except Pro and Y is Ser or Thr. Appropriate substitutions, additions, or deletions to the nucleotide sequence encoding these triplets will result in prevention of attachment of carbohydrate residues at the Asn side chain. Alteration of a single nucleotide, chosen so that Asn is replaced by a different amino acid, for example, is sufficient to inactivate an N-glycosylation site. Known procedures for inactivating N-glycosylation sites in proteins include those described in U.S. Patent 5,071,972 and EP 276,846, hereby incorporated by reference.

10

Appropriate substitutions, additions, or deletions to the nucleotide sequence encoding these triplets will result in prevention of attachment of carbohydrate residues at the Asn side chain. Alteration of a single nucleotide, chosen so that Asn is replaced by a different amino acid, for example, is sufficient to inactivate an N-glycosylation site. Known procedures for inactivating N-glycosylation sites in proteins include those described in U.S. Patent 5,071,972 and EP 276,846, hereby incorporated by reference.

15

In another example, sequences encoding Cys residues that are not essential for biological activity can be altered to cause the Cys residues to be deleted or replaced with other amino acids, preventing formation of incorrect intramolecular disulfide bridges upon renaturation. Other equivalents are prepared by modification of adjacent dibasic amino acid residues to enhance expression in yeast systems in which KEX2 protease activity is present. EP 212,914 discloses the use of site-specific mutagenesis to inactivate KEX2 protease processing sites in a protein. KEX2 protease processing sites are inactivated by deleting, adding, or substituting residues to alter Arg-Arg, Arg-Lys, and Lys-Arg pairs to eliminate the occurrence of these adjacent basic residues. Lys-Lys pairings are considerably less susceptible to KEX2 cleavage, and conversion of Arg-Lys or Lys-Arg to Lys-Lys represents a conservative and preferred approach to inactivating KEX2 sites.

20

Known procedures for inactivating N-glycosylation sites in proteins include those described in U.S. Patent 5,071,972 and EP 276,846, hereby incorporated by reference.

25

In another example, sequences encoding Cys residues that are not essential for biological activity can be altered to cause the Cys residues to be deleted or replaced with other amino acids, preventing formation of incorrect intramolecular disulfide bridges upon renaturation. Other equivalents are prepared by modification of adjacent dibasic amino acid residues to enhance expression in yeast systems in which KEX2 protease activity is present. EP 212,914 discloses the use of site-specific mutagenesis to inactivate KEX2 protease processing sites in a protein. KEX2 protease processing sites are inactivated by deleting, adding, or substituting residues to alter Arg-Arg, Arg-Lys, and Lys-Arg pairs to eliminate the occurrence of these adjacent basic residues. Lys-Lys pairings are considerably less susceptible to KEX2 cleavage, and conversion of Arg-Lys or Lys-Arg to Lys-Lys represents a conservative and preferred approach to inactivating KEX2 sites.

30

The invention further encompasses isolated fragments and oligonucleotides derived from the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 13 or 15. Nucleic acid sequences within the scope of the invention include isolated DNA and RNA sequences that hybridize to the native nucleotide sequences disclosed herein under

35

conditions of moderate or severe stringency, and which encode polypeptides or fragments thereof of the invention. These isolated DNA and RNA sequences also include full length DNA or RNA molecules encoding for polypeptides with kinase activity. As used herein, conditions of moderate stringency, as known to those having ordinary skill in the art, and as defined by Sambrook et al. *Molecular Cloning: A Laboratory Manual*, 2 ed.

40

45

50

55

5

Vol. 1, pp. 1.101-104, Cold Spring Harbor Laboratory Press, (1989), include use of a prewashing solution for the nitrocellulose filters 5X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0), hybridization conditions of 50% formamide, 6X SSC at 42°C (or other similar hybridization solution, such as Stark's solution, in 50% formamide at 42°C), and washing conditions of about 60°C, 0.5X SSC, 0.1% SDS. Conditions of high stringency are defined as hybridization conditions as above, and with washing at 68°C, 0.2X SSC, 0.1% SDS. The skilled artisan will recognize that the temperature and wash solution salt concentration can be adjusted as necessary according to factors such as the length of the probe.

10

10 Due to the known degeneracy of the genetic code, wherein more than one codon can encode the same amino acid, a DNA sequence can vary from that shown in SEQ ID NO: 1, 2, 3, 4, 5, 6, 13 or 15, and still encode a polypeptide having the amino acid sequence of SEQ ID NO:7, 8, 9, 10, 11, 12, 14 or 16. Such variant DNA sequences can result from silent mutations (e.g., occurring during PCR amplification), or can be the product of deliberate mutagenesis of a native sequence.

15

15 The invention thus provides equivalent isolated DNA sequences encoding polypeptides of the invention, selected from: (a) DNA derived from the coding region of a native mammalian gene; (b) cDNA comprising the nucleotide sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 13 or 15; (c) DNA encoding the polypeptides of SEQ ID NO:7, 8, 9, 10, 11, 12, 14 or 16; (d) DNA capable of hybridization to a DNA of (a) under conditions of moderate stringency and which encodes polypeptides of the invention; and (e) DNA which is degenerate as a result of the genetic code to a DNA defined in (a), (b), (c), or (d) and which encodes polypeptides of the invention. Of course, polypeptides encoded by such DNA equivalent sequences are encompassed by the invention.

20

20 25 DNA that is equivalent to the DNA sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 13 or 15 will hybridize under moderately stringent conditions to the double-stranded native DNA sequence that encode polypeptides comprising amino acid sequences of SEQ ID NO:7, 8, 9, 10, 11, 12, 14 or 16. Examples of polypeptides encoded by such DNA, include, but are not limited to, polypeptide fragments and polypeptides comprising 30 inactivated N-glycosylation site(s), inactivated protease processing site(s), or conservative amino acid substitution(s), as described above. Polypeptides encoded by DNA derived from other mammalian species, wherein the DNA will hybridize to the complement of the DNA of SEQ ID NO: 1, 2, 3, 4, 5, 6, 13 or 15 are also encompassed.

25

30

35

40

45

50

55

5

Recombinant expression vectors containing a nucleic acid sequence encoding polypeptides of the invention can be prepared using well known methods. The expression vectors include a DNA sequence of the invention operably linked to suitable transcriptional or translational regulatory nucleotide sequences, such as those derived

10

from a mammalian, microbial, viral, or insect gene. Examples of regulatory sequences include transcriptional promoters, operators, or enhancers, an mRNA ribosomal binding site, and appropriate sequences which control transcription and translation initiation and termination. Nucleotide sequences are "operably linked" when the regulatory sequence functionally relates to the DNA sequence of the invention. Thus, a promoter nucleotide sequence is operably linked to a DNA sequence if the promoter nucleotide sequence controls the transcription of the DNA sequence of the invention. The ability to replicate in the desired host cells, usually conferred by an origin of replication, and a selection gene by which transformants are identified can additionally be incorporated into the expression vector.

15

In addition, sequences encoding appropriate signal peptides that are not naturally associated with polypeptides of the invention can be incorporated into expression vectors. For example, a DNA sequence for a signal peptide (secretory leader) can be fused in-frame to the nucleotide sequence of the invention so that the polypeptide is initially translated as a fusion protein comprising the signal peptide. A signal peptide that is functional in the intended host cells enhances extracellular secretion of the polypeptide. The signal peptide can be cleaved from the polypeptide upon secretion of polypeptide from the cell.

20

Suitable host cells for expression of polypeptides of the invention include prokaryotes, yeast or higher eukaryotic cells. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described, for example, in Pouwels et al. *Cloning Vectors: A Laboratory Manual*, Elsevier, New York, (1985). Cell-free translation systems could also be employed to produce polypeptides of the invention using RNAs derived from DNA constructs disclosed herein.

25

Prokaryotes include gram negative or gram positive organisms, for example, *E. coli* or *Bacilli*. Suitable prokaryotic host cells for transformation include, for example, *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium*, and various other species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*. In a prokaryotic host cell, such as *E. coli*, a polypeptide of the invention can include an N-terminal methionine residue to

30

5

facilitate expression of the recombinant polypeptide in the prokaryotic host cell. The N-terminal Met can be cleaved from the expressed recombinant polypeptide.

10

Expression vectors for use in prokaryotic host cells generally comprise one or more phenotypic selectable marker genes. A phenotypic selectable marker gene is, for example, a gene encoding a protein that confers antibiotic resistance or that supplies an autotrophic requirement. Examples of useful expression vectors for prokaryotic host cells include those derived from commercially available plasmids such as the cloning vector pBR322 (ATCC 37017). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells. To construct an expression vector using pBR322, an appropriate promoter and a DNA sequence of the invention are inserted into the pBR322 vector. Other commercially available vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM1 (Promega Biotec, Madison, WI, USA). Other commercially available vectors include those that are specifically designed for the expression of proteins; these would include pMAL-p2 and pMAL-c2 vectors that are used for the expression of proteins fused to maltose binding protein (New England Biolabs, Beverly, MA, USA).

15

20

25

Promoter sequences commonly used for recombinant prokaryotic host cell expression vectors include  $\beta$ -lactamase (penicillinase), lactose promoter system (Chang et al., *Nature* 275:615, 1978; and Goeddel et al., *Nature* 281:544, 1979), tryptophan (trp) promoter system (Goeddel et al., *Nucl. Acids Res.* 8:4057, 1980; and EP-A-36776), and tac promoter (Maniatis, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, p. 412, 1982). A particularly useful prokaryotic host cell expression system employs a phage  $\lambda P_L$  promoter and a cl857ts thermolabile repressor sequence. Plasmid vectors available from the American Type Culture Collection, which incorporate derivatives of the  $\lambda P_L$  promoter, include plasmid pHUB2 (resident in *E. coli* strain JMB9 (ATCC 37092)) and pPLc28 (resident in *E. coli* RR1 (ATCC 53082)).

30

35

40

DNA of the invention can be cloned in-frame into the multiple cloning site of an ordinary bacterial expression vector. Ideally the vector contains an inducible promoter upstream of the cloning site, such that addition of an inducer leads to high-level production of the recombinant protein at a time of the investigator's choosing. For some proteins, expression levels can be boosted by incorporation of codons encoding a fusion partner (such as hexahistidine) between the promoter and the gene of interest. The

50

5

resulting "expression plasmid" can be propagated in a variety of prokaryotic hosts such as *E. coli*.

10

For expression of the recombinant protein, the bacterial cells are propagated in growth medium until reaching a pre-determined optical density. Expression of the recombinant protein is then induced, e.g. by addition of IPTG (isopropyl-β-D-thiogalactopyranoside), which activates expression of proteins from plasmids containing a lac operator/promoter. After induction (typically for 1-4 hours), the cells are harvested by pelleting in a centrifuge, e.g. at 5,000 x G for 20 minutes at 4°C.

15

For recovery of the expressed protein, the pelleted cells may be resuspended in ten volumes of 50 mM Tris-HCl (pH 8)/1 M NaCl and then passed two or three times through a French press. Most highly-expressed recombinant proteins form insoluble aggregates known as inclusion bodies. Inclusion bodies can be purified away from the soluble proteins by pelleting in a centrifuge at 5,000 x G for 20 minutes, 4°C. The inclusion body pellet is washed with 50 mM Tris-HCl (pH 8)/1% Triton X-100 and then dissolved in 50 mM Tris-HCl (pH 8)/8 M urea/0.1 M DTT. Any material that cannot be dissolved is removed by centrifugation (10,000 x G for 20 minutes, 20°C). The protein of interest will, in most cases, be the most abundant protein in the resulting clarified supernatant. This protein may be "refolded" into the active conformation by dialysis against 50 mM Tris-HCl (pH 8)/5 mM CaCl<sub>2</sub>/5 mM Zn(OAc)<sub>2</sub>/1 mM GSSG/0.1 mM GSH. After refolding, purification can be carried out by a variety of chromatographic methods such as ion exchange or gel filtration. In some protocols, initial purification may be carried out before refolding. As an example, hexahistidine-tagged fusion proteins may be partially purified on immobilized nickel.

20

25

30

35

While the preceding purification and refolding procedure assumes that the protein is best recovered from inclusion bodies, those skilled in the art of protein purification will appreciate that many recombinant proteins are best purified out of the soluble fraction of cell lysates. In these cases, refolding is often not required, and purification by standard chromatographic methods can be carried out directly.

Polypeptides of the invention alternatively can be expressed in yeast host cells,

40

preferably from the *Saccharomyces* genus (e.g., *S. cerevisiae*). Other genera of yeast, such as *Pichia*, *K. lactis*, or *Kluyveromyces*, can also be employed. Yeast vectors will often contain an origin of replication sequence from a 2μ yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, sequences for polyadenylation, sequences

50

5 for transcription termination, and a selectable marker gene. Suitable promoter sequences  
for yeast vectors include, among others, promoters for metallothionein, 3-  
10 phosphoglycerate kinase (Hitzeman et al., *J. Biol. Chem.* 255:2073, 1980), or other  
glycolytic enzymes (Hess et al., *J. Adv. Enzyme Reg.* 7:149, 1968; and Holland et al.,  
15 *Biochem.* 17:4900, 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase,  
hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate  
isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase,  
15 phosphoglucose isomerase, and glucokinase. Other suitable vectors and promoters for  
use in yeast expression are further described in Hitzeman, EPA-73,657 or in Fleer et. al.,  
10 *Gene*, 107:285-195 (1991); and van den Berg et. al., *Bio/Technology*, 8:135-139 (1990).  
Another alternative is the glucose-repressible ADH2 promoter described by Russell et al.  
20 (*J. Biol. Chem.* 258:2674, 1982) and Beier et al. (*Nature* 300:724, 1982). Shuttle vectors  
replicable in both yeast and *E. coli* can be constructed by inserting DNA sequences from  
pBR322 for selection and replication in *E. coli* (Amp<sup>r</sup> gene and origin of replication) into  
25 the above-described yeast vectors.

The yeast  $\alpha$ -factor leader sequence can be employed to direct secretion of a  
polypeptide of the invention. The  $\alpha$ -factor leader sequence is often inserted between the  
30 promoter sequence and the structural gene sequence. See, e.g., Kurjan et al., *Cell* 30:933,  
1982; Bitter et al., *Proc. Natl. Acad. Sci. USA* 81:5330, 1984; U. S. Patent 4,546,082; and  
35 EP 324,274. Other leader sequences suitable for facilitating secretion of recombinant  
polypeptides from yeast hosts are known to those of skill in the art. A leader sequence  
can be modified near its 3' end to contain one or more restriction sites. This will facilitate  
fusion of the leader sequence to the structural gene.

Yeast transformation protocols are known to those of skill in the art. One such  
40 protocol is described by Hinnen et al., *Proc. Natl. Acad. Sci. USA* 75:1929, 1978. The  
Hinnen et al. protocol selects for Trp<sup>r</sup> transformants in a selective medium, wherein the  
selective medium consists of 0.67% yeast nitrogen base, 0.5% casamino acids, 2%  
glucose, 10  $\mu$ g/ml adenine, and 20  $\mu$ g/ml uracil.

Yeast host cells transformed by vectors containing ADH2 promoter sequence can  
45 be grown for inducing expression in a "rich" medium. An example of a rich medium is  
one consisting of 1% yeast extract, 2% peptone, and 1% glucose supplemented with 80  
 $\mu$ g/ml adenine and 80  $\mu$ g/ml uracil. Derepression of the ADH2 promoter occurs when  
glucose is exhausted from the medium.

50

5

Mammalian or insect host cell culture systems could also be employed to express recombinant polypeptides of the invention. Baculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, *Bio/Technology* 6:47 (1988). Established cell lines of mammalian origin also can be employed. Examples of suitable mammalian host cell lines include the COS-7 line of monkey kidney cells (ATCC CRL 1651) (Gluzman et al., *Cell* 23:175, 1981), L cells, C127 cells, 3T3 cells (ATCC CCL 163), Chinese hamster ovary (CHO) cells, HeLa cells, and BHK (ATCC CRL 10) cell lines, and the CV-1/EBNA-1 cell line (ATCC CRL 10478) derived from the African green monkey kidney cell line CVI (ATCC CCL 70) as described by McMahan et al. (*EMBO J.* 10: 2821, 1991).

20

Established methods for introducing DNA into mammalian cells have been described (Kaufman, R.J., *Large Scale Mammalian Cell Culture*, 1990, pp. 15-69). Additional protocols using commercially available reagents, such as Lipofectamine (Gibco/BRL) or Lipofectamine-Plus, can be used to transfect cells (Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413-7417, 1987). In addition, electroporation can be used to transfect mammalian cells using conventional procedures, such as those in Sambrook et al. *Molecular Cloning: A Laboratory Manual*, 2 ed. Vol. 1-3, Cold Spring Harbor Laboratory Press, 1989). Selection of stable transformants can be performed using methods known in the art, such as, for example, resistance to cytotoxic drugs. Kaufman et al., *Meth. in Enzymology* 185:487-511, 1990, describes several selection schemes, such as dihydrofolate reductase (DHFR) resistance. A suitable host strain for DHFR selection can be CHO strain DX-B11, which is deficient in DHFR (Urlaub and Chasin, *Proc. Natl. Acad. Sci. USA* 77:4216-4220, 1980). A plasmid expressing the DHFR cDNA can be introduced into strain DX-B11, and only cells that contain the plasmid can grow in the appropriate selective media. Other examples of selectable markers that can be incorporated into an expression vector include cDNAs conferring resistance to antibiotics, such as G418 and hygromycin B. Cells harboring the vector can be selected on the basis of resistance to these compounds.

35

40

45

50

Transcriptional and translational control sequences for mammalian host cell expression vectors can be excised from viral genomes. Commonly used promoter sequences and enhancer sequences are derived from polyoma virus, adenovirus 2, simian virus 40 (SV40), and human cytomegalovirus. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early and late promoter, enhancer, splice, and polyadenylation sites can be used to provide other genetic elements for expression of a

5

structural gene sequence in a mammalian host cell. Viral early and late promoters are particularly useful because both are easily obtained from a viral genome as a fragment, which can also contain a viral origin of replication (Fiers et al., *Nature* 273:113, 1978; Kaufman, *Meth. in Enzymology*, 1990). Smaller or larger SV40 fragments can also be used, provided the approximately 250 bp sequence extending from the *Hind* III site toward the *Bgl* I site located in the SV40 viral origin of replication site is included.

10

Additional control sequences shown to improve expression of heterologous genes from mammalian expression vectors include such elements as the expression augmenting sequence element (EASE) derived from CHO cells (Morris et al., *Animal Cell*

15

10 *Technology*, 1997, pp. 529-534) and the tripartite leader (TPL) and VA gene RNAs from Adenovirus 2 (Gingeras et al., *J. Biol. Chem.* 257:13475-13491, 1982). The internal ribosome entry site (IRES) sequences of viral origin allows dicistronic mRNAs to be translated efficiently (Oh and Sarnow, *Current Opinion in Genetics and Development* 3:295-300, 1993; Ramesh et al., *Nucleic Acids Research* 24:2697-2700, 1996).

20

15 Expression of a heterologous cDNA as part of a dicistronic mRNA followed by the gene for a selectable marker (e.g. DHFR) has been shown to improve transfectability of the host and expression of the heterologous cDNA (Kaufman, *Meth. in Enzymology*, 1990). Exemplary expression vectors that employ dicistronic mRNAs are pTR-DC/GFP described by Mosser et al., *Biotechniques* 22:150-161, 1997, and p2A5I described by

25

20 Morris et al., *Animal Cell Technology*, 1997, pp. 529-534.

30

25 A useful high expression vector, pCAVNOT, has been described by Mosley et al., *Cell* 59:335-348, 1989. Other expression vectors for use in mammalian host cells can be constructed as disclosed by Okayama and Berg (*Mol. Cell. Biol.* 3:280, 1983). A useful system for stable high level expression of mammalian cDNAs in C127 murine mammary

35

25 epithelial cells can be constructed substantially as described by Cosman et al. (*Mol. Immunol.* 23:935, 1986). A useful high expression vector, PMLSV N1/N4, described by Cosman et al., *Nature* 312:768, 1984, has been deposited as ATCC 39890. Additional useful mammalian expression vectors are described in EP-A-0367566, and in U.S. Patent Application Serial No. 07/701,415, filed May 16, 1991, incorporated by reference herein.

40

30 The vectors can be derived from retroviruses. In place of the native signal sequence, a heterologous signal sequence can be added, such as the signal sequence for IL-7 described in United States Patent 4,965,195; the signal sequence for IL-2 receptor described in Cosman et al., *Nature* 312:768 (1984); the IL-4 signal peptide described in EP 367,566; the type I IL-1 receptor signal peptide described in U.S. Patent 4,968,607;

45

50

5

and the type II IL-1 receptor signal peptide described in EP 460,846. Another useful expression vector, pFLAG, can be used. FLAG technology is centered on the fusion of a low molecular weight (1kD), hydrophilic, FLAG marker peptide to the N-Terminus of a recombinants protein expressed by the pFLAG-1™ Expression Vector (1) (obtained from IBI Kodak).

10

An isolated and purified polypeptide according to the invention can be produced by recombinant expression systems as described above or purified from naturally occurring cells. Polypeptides can be substantially purified, as indicated by a single protein band upon analysis by SDS-polyacrylamide gel electrophoresis (SDS-PAGE).

15

One process for producing polypeptides of the invention comprises culturing a host cell transformed with an expression vector comprising a DNA sequence that encodes a polypeptide of the invention under conditions sufficient to promote expression of the polypeptide. The polypeptide is then recovered from culture medium or cell extracts, depending upon the expression system employed. As is known to the skilled artisan,

20

procedures for purifying a recombinant protein will vary according to such factors as the type of host cells employed and whether or not the recombinant protein is secreted into the culture medium. For example, when expression systems that secrete the recombinant protein are employed, the culture medium first can be concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon

25

ultrafiltration unit. Following the concentration step, the concentrate can be applied to a purification matrix such as a gel filtration medium. Alternatively, an anion exchange resin can be employed, for example, a matrix or substrate having pendant

30

diethylaminoethyl (DEAE) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Alternatively, a

35

cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred. Finally, one or more reversed-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, (e.g., silica

40

gel having pendant methyl or other aliphatic groups) can be employed to further purify the polypeptides. Some or all of the foregoing purification steps, in various combinations, are well known and can be employed to provide an isolated and purified recombinant protein.

It is possible to utilize an affinity column comprising a polypeptide-binding protein of the invention, such as a monoclonal antibody generated against polypeptides of

45

50

55

5 the invention, to affinity-purify expressed polypeptides. These polypeptides can be  
10 removed from an affinity column using conventional techniques, e.g., in a high salt  
elution buffer and then dialyzed into a lower salt buffer for use or by changing pH or  
15 other components depending on the affinity matrix utilized.

5 In this aspect of the invention, polypeptide-binding proteins, such as the anti-  
10 polypeptide antibodies of the invention, can be bound to a solid phase such as a column  
chromatography matrix or a similar substrate suitable for identifying, separating, or  
15 purifying cells that express polypeptides of the invention on their surface. Adherence of  
20 polypeptide-binding proteins of the invention to a solid phase contacting surface can be  
accomplished by any means, for example, magnetic microspheres can be coated with  
25 these polypeptide-binding proteins and held in the incubation vessel through a magnetic  
field. Suspensions of cell mixtures are contacted with the solid phase that has such  
30 polypeptide-binding proteins thereon. Cells having polypeptides of the invention on their  
surface bind to the fixed polypeptide-binding protein and unbound cells then are washed  
35 away. This affinity-binding method is useful for purifying, screening, or separating such  
40 polypeptide-expressing cells from solution. Methods of releasing positively selected cells  
from the solid phase are known in the art and encompass, for example, the use of  
enzymes. Such enzymes are preferably non-toxic and non-injurious to the cells and are  
45 preferably directed to cleaving the cell-surface binding partner.

20 Alternatively, mixtures of cells suspected of containing polypeptide-expressing  
25 cells of the invention first can be incubated with a biotinylated polypeptide-binding  
30 protein of the invention. Incubation periods are typically at least one hour in duration to  
35 ensure sufficient binding to polypeptides of the invention. The resulting mixture then is  
40 passed through a column packed with avidin-coated beads, whereby the high affinity of  
45 biotin for avidin provides the binding of the polypeptide-binding cells to the beads. Use  
50 of avidin-coated beads is known in the art. See Berenson, et al. *J. Cell. Biochem.*,  
10D:239 (1986). Wash of unbound material and the release of the bound cells is  
performed using conventional methods.

55 In the methods described above, suitable polypeptide-binding proteins are anti-  
60 polypeptide antibodies, and other proteins that are capable of high-affinity binding of  
65 polypeptides of the invention. A preferred polypeptide-binding protein is an polypeptide  
70 monoclonal antibody.

75 Recombinant protein produced in bacterial culture is usually isolated by initial  
80 disruption of the host cells, centrifugation, extraction from cell pellets if an insoluble

5

polypeptide, or from the supernatant fluid if a soluble polypeptide, followed by one or more concentration, salting-out, ion exchange, affinity purification or size exclusion chromatography steps. Finally, RP-HPLC can be employed for final purification steps. Microbial cells can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.

10

Transformed yeast host cells are preferably employed to express polypeptides of the invention as a secreted polypeptide in order to simplify purification. Secreted recombinant polypeptide from a yeast host cell fermentation can be purified by methods analogous to those disclosed by Urdal et al. (*J. Chromatog.* 296:171, 1984). Urdal et al. describe two sequential, reversed-phase HPLC steps for purification of recombinant human IL-2 on a preparative HPLC column.

20

In yet another embodiment of the invention, antisense or sense oligonucleotides comprising a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to a target mRNA sequence (forming a duplex) or to the sequence in the double-stranded DNA helix (forming a triple helix) can be made according to the invention. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment of the coding region of cDNA (SEQ ID NO: 1, 2, 3, 4, 5, 6, 13 or 15). Such a fragment generally comprises at least about 14 nucleotides, preferably from about 14 to about 30 nucleotides. The ability to create an antisense or a sense oligonucleotide, based upon a cDNA sequence for a given protein is described in, for example, Stein and Cohen, *Cancer Res.* 48:2659, 1988 and van der Krol et al., *BioTechniques* 6:958, 1988.

Binding of antisense or sense oligonucleotides to target nucleic acid sequences results in the formation of complexes that block translation (RNA) or transcription (DNA) by one of several means, including enhanced degradation of the duplexes, premature

termination of transcription or translation, or by other means. The antisense oligonucleotides thus can be used to block expression of polypeptides of the invention. Antisense or sense oligonucleotides further comprise oligonucleotides having modified sugar-phosphodiester backbones (or other sugar linkages, such as those described in WO 91/06629) and wherein such sugar linkages are resistant to endogenous nucleases. Such oligonucleotides with resistant sugar linkages are stable *in vivo* (i.e., capable of resisting enzymatic degradation), but retain sequence specificity to be able to bind to target nucleotide sequences. Other examples of sense or antisense oligonucleotides include those oligonucleotides that are covalently linked to organic moieties, such as those described in WO 90/10448, and other moieties that increase affinity of the

5

oligonucleotide for a target nucleic acid sequence, such as poly-(L-lysine). Further still, intercalating agents, such as ellipticine, and alkylating agents or metal complexes can be attached to sense or antisense oligonucleotides to modify binding specificities of the antisense or sense oligonucleotide for the target nucleotide sequence.

10

5 Antisense or sense oligonucleotides can be introduced into a cell containing the target nucleic acid sequence by any gene transfer method, including, for example,  $\text{CaPO}_4$ -mediated DNA transfection, electroporation, or by using gene transfer vectors such as 15 Epstein-Barr virus. Antisense or sense oligonucleotides are preferably introduced into a cell containing the target nucleic acid sequence by insertion of the antisense or sense 20 oligonucleotide into a suitable retroviral vector, then contacting the cell with the retrovirus vector containing the inserted sequence, either *in vivo* or *ex vivo*. Suitable retroviral vectors include, but are not limited to, the murine retrovirus M-MuLV, N2 (a retrovirus derived from M-MuLV), or the double copy vectors designated DCT5A, DCT5B and DCT5C (see PCT Application US 90/02656).

25

15 Alternatively, sense or antisense oligonucleotides also can be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand 30 binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand 35 binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell.

35

In yet another embodiment, a sense or an antisense oligonucleotide can be 40 introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90/10448. The sense or antisense 45 oligonucleotide-lipid complex is preferably dissociated within the cell by an endogenous lipase.

Another embodiment of the invention relates to therapeutic uses of kinases. Kinases play a central role in cellular signal transduction. As such, alterations in kinase 50 expression and/or activation can have profound effects on a plethora of cellular processes, including, but not limited to, activation or inhibition of cell specific responses, proliferation, and programmed cell death (apoptosis). Over expression of cloned kinases or of catalytically inactive mutants of kinases has been used to identify the role a particular kinase plays in mediating specific signaling events.

5

Kinase mediated cellular signaling often involves a molecular activation cascade, during which an activated kinase propagates a ligand-receptor mediated signal by specifically phosphorylating target substrates. These substrates can themselves be

10

kinases which become activated following phosphorylation. Alternatively, they can be

15

5 adaptor molecules that facilitate down stream signaling through protein-protein interaction following phosphorylation. Regardless of the nature of the substrate molecule(s), expressed catalytically active versions of the putative kinases in the invention can be used to identify what substrate(s) were recognized and phosphorylated by the kinase(s) of the invention. As such, these kinases can be used as reagents to

10 identify novel molecules involved in signal transduction pathways.

20

Knowledge of a particular kinase would enable one to enzymatically label the

substrate with  $^{32}\text{P}$  thereby facilitating identification and also to use the resultant

radiolabeled protein or a peptide derived from a certain region of the protein as a

substrate probe to identify and isolate specific phosphatases. Phosphatases are enzymes

25

15 whose function is to remove phosphates from selected phosphoproteins; they perform the reverse function of kinases.

30

In some systems specific glycosylations with N-acetyl glucosamine residues have

been described as a biological counter balance to kinases. That is, glycosidases have been

suggested to compete with kinases for the same serine or threonine residues to covalently

20 modify. Therefore, the kinase can be used to dissect dynamic interactions between kinase and phosphatase, and also between kinase and glycosidase, and finally to examine the dynamic interactions among kinase, phosphatase and glycosidase together.

35

Kinases phosphorylate target serine, threonine or tyrosine residues in the context of specific recognition motifs. Recognition motifs can consist solely of primary structure

25 or in some cases recognition requires more complex structural features. One can take advantage of kinases with strict primary sequence recognition requirements by using them as a general labeling reagent. Nucleotides coding for the amino acids recognized by a particular kinase could be engineered onto either end of a protein of interest, thereby "tagging" the molecule. The expressed, tagged protein could be  $^{32}\text{P}$ -labeled at a known

40 site on the engineered tag by its specific kinase, thus generating a well defined, radiolabeled protein.

Because kinases are phosphotransferases, they must take part in protein-protein interactions with at least one or more substrate molecules, i.e. its phosphate recipient(s).

50 Therefore, kinases or polypeptides comprised of portions of a kinase could be used as

5

“baits” in the yeast two hybrid system by well established molecular biology techniques, to identify molecules that interact directly with the polypeptide.

10

Alternatively, polypeptides of the invention could be engineered prior to expression with a tag such as poly-His or FLAG, then be expressed and purified using

15

either nickel chelate chromatography or anti-FLAG antibody coupled to a resin, respectively. Once bound to the resin, the polypeptide of the invention could be covalently attached using a bifunctional cross-linking agent using well established techniques. The covalently bound polypeptide to the resin could then be used to purify molecules from cell lysates or cell supernatants (following treatment with various

10 reagent) through their affinity for the polypeptide of the invention.

20

Isolated and purified kinase polypeptides or a fragment thereof of the invention can also be useful as a therapeutic agent in inhibiting signaling. Polypeptides are introduced into the intracellular environment by well-known means, such as by encasing the protein in liposomes or coupling it to a monoclonal antibody targeted to a specific cell

25

15 type.

30

DNA, polypeptides, and antibodies against polypeptides of the invention can be used as reagents in a variety of research protocols. A sample of such research protocols are given in Sambrook et al. *Molecular Cloning: A Laboratory Manual*, 2 ed. Vol. 1-3, Cold Spring Harbor Laboratory Press, (1989). For example, these reagents can serve as

20 markers for cell specific or tissue specific expression of RNA or proteins. Similarly, these reagents can be used to investigate constitutive and transient expression of RNA or polypeptides. The DNA can be used to determine the chromosomal location of DNA and to map genes in relation to this chromosomal location. The DNA can also be used to

35

30 examine genetic heterogeneity and heredity through the use of techniques such as genetic fingerprinting, as well as to identify risks associated with genetic disorders. The DNA can be further used to identify additional genes related to the DNA and to establish evolutionary trees based on the comparison of sequences. The DNA and polypeptides can be used to select for those genes or proteins that are homologous to the DNA or polypeptides, through positive screening procedures such as Southern blotting and

40

45 immunoblotting and through negative screening procedures such as subtraction.

50

The polypeptides and fragments of the invention can also be used as a reagent to identify (a) any protein that polypeptide regulates, and (b) other proteins with which it might interact. Polypeptides could be used by coupling recombinant protein to an affinity matrix, or by using them as a bait in the 2-hybrid system. The polypeptides and

5

fragments thereof can be used as reagents in the study of the kinase signaling pathway as a reagent to block kinase signaling.

10

A hallmark of protein kinases is their ability to phosphorylate other proteins and

15

to auto-phosphorylate. Therefore, in one aspect of the invention, the isolated polypeptides with kinase activity can be used in assays to phosphorylate target proteins, radiolabel target proteins with  $^{32}\text{P}$ , and identify proteins having phosphatase activity.

20

Exemplary methods of phosphorylation assays set forth above are disclosed in U.S. Patents 5,447,860 which is incorporated herein by reference. In addition to full length

25

polypeptides, the invention also includes the isolated active kinase domains of kinases,

30

such as the intracellular domain of transmembrane bound kinases and the cytoplasmic kinases, which can function as reagents in kinase assays. Further, soluble forms of the extracellular domains of the kinases are useful in inhibiting the natural ligand-receptor interaction.

35

When used as a therapeutic agent, polypeptides of the invention can be formulated

40

into pharmaceutical compositions according to known methods. The polypeptides can be combined in admixture, either as the sole active material or with other known active materials, with pharmaceutically suitable diluents (e.g., Tris-HCl, acetate, phosphate), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), emulsifiers, solubilizers, adjuvants and/or carriers. Suitable carriers and their formulations are described in

45

Remington's Pharmaceutical Sciences, 16th ed. 1980, Mack Publishing Co. In addition, such compositions can contain the polypeptides complexed with polyethylene glycol (PEG), metal ions, or incorporated into polymeric compounds such as polyacetic acid, polyglycolic acid, hydrogels, etc., or incorporated into liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts or spheroblasts. Such compositions will influence the physical state, solubility, stability, rate of *in vivo* release, and rate of *in vivo* clearance of polypeptides of the invention.

50

The dosage of the composition can be readily determined by those of ordinary skill in the art. The amount to be administered and the frequency of administration can be determined empirically and will take into consideration the age and size of the patient being treated, as well as the malady being treated.

55

Treatment comprises administering the composition by any method familiar to those of ordinary skill in the art, including intravenous, intraperitoneal, intracorporeal injection, intra-articular, intraventricular, intrathecal, intramuscular, subcutaneous, topically, tonsillar, intranasally, intravaginally, and orally. The composition may also be

5

given locally, such as by injection into the particular area, either intramuscularly or subcutaneously.

10

Within the therapeutic and research aspects of the invention, polypeptides of the invention, and peptides based on the amino acid sequence thereof, can be utilized to 5 prepare antibodies that specifically bind to the polypeptides. The term "antibodies" is meant to include polyclonal antibodies, monoclonal antibodies, fragments thereof such as F(ab')2, and Fab fragments, as well as any recombinantly produced binding partners.

15

Antibodies are defined to be specifically binding if they bind polypeptides of the invention with a  $K_d$  of greater than or equal to about  $10^7$  M $^{-1}$ . Affinities of binding

10 partners or antibodies can be readily determined using conventional techniques, for example those described by Scatchard et al., *Ann. N.Y Acad. Sci.*, 51:660 (1949).

20

25 Polyclonal antibodies can be readily generated from a variety of sources, for example, horses, cows, goats, sheep, dogs, chickens, rabbits, mice, or rats, using procedures that are well-known in the art. In general, purified polypeptides of the

invention, or a peptide based on the amino acid sequence of polypeptides of the invention 15 that is appropriately conjugated, is administered to the host animal typically through parenteral injection. The immunogenicity of these polypeptides can be enhanced through the use of an adjuvant, for example, Freund's complete or incomplete adjuvant.

30

35 Following booster immunizations, small samples of serum are collected and tested for reactivity to the polypeptides. Examples of various assays useful for such determination 20 include those described in: *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988; as well as procedures such as countercurrent immuno-electrophoresis (CIEP), radioimmunoassay, radio-immunoprecipitation, enzyme-linked immuno-sorbent assays (ELISA), dot blot assays, and sandwich assays, see U.S. 25 Patent Nos. 4,376,110 and 4,486,530.

40

45 Monoclonal antibodies can be readily prepared using well-known procedures, see for example, the procedures described in U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439, and 4,411,993; *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, Kennett, McKearn, and Bechtol (eds.), 1980. Briefly, 30 the host animals, such as Balb/c mice are injected intraperitoneally at least once, and preferably at least twice at about 3 week intervals with isolated and purified polypeptides or conjugated polypeptides of the invention, optionally in the presence of adjuvant. 10  $\mu$ g of isolated and purified polypeptide of the invention or peptides based on the amino acid sequence of polypeptides of the invention in the presence of RIBI adjuvant (RIBI 50

5

Corp., Hamilton, Montana). Mouse sera are then assayed by conventional dot blot technique or antibody capture (ABC) to determine which animal produces the highest level of antibody and whose spleen cells are the best candidate for fusion. Approximately two to three weeks later, the mice are given an intravenous boost of the polypeptides or conjugated polypeptides such as 3 $\mu$ g suspended in sterile PBS. Mice are later sacrificed and spleen cells fused with commercially available myeloma cells, such as Ag8.653 (ATCC), following established protocols. Briefly, the myeloma cells are washed several times in media and fused to mouse spleen cells at a ratio of about three spleen cells to one myeloma cell. The fusing agent can be any suitable agent used in the art, for example, polyethylene glycol (PEG) or more preferably, 50% PEG: 10% DMSO (Sigma). Fusion is plated out into, for example, twenty 96-well flat bottom plates (Corning) containing an appropriate medium, such as HAT supplemented DMEM media and allowed to grow for eight days. Supernatants from resultant hybridomas are collected and added to, for example, a 96-well plate for 60 minutes that is first coated with goat anti-mouse Ig. Following washes,  $^{125}$ I-polypeptide or peptides of the invention are added to each well, incubated for 60 minutes at room temperature, and washed four times. Positive wells can be subsequently detected by conventional methods, such as autoradiography at -70°C using Kodak X-Omat S film. Positive clones can be grown in bulk culture and supernatants are subsequently purified, such as over a Protein A column (Pharmacia). It is understood of course that many techniques could be used to generate antibodies against polypeptides and fragmented peptides of the invention and that this embodiment in no way limits the scope of the invention.

35

The monoclonal antibodies of the invention can be produced using alternative techniques, such as those described by Alting-Mees et al., "Monoclonal Antibody

40

25 Expression Libraries: A Rapid Alternative to Hybridomas", *Strategies in Molecular Biology* 3:1-9 (1990), which is incorporated herein by reference. Similarly, binding partners can be constructed using recombinant DNA techniques to incorporate the variable regions of a gene that encodes a specific binding antibody. Such a technique is described in Larrick et al., *Biotechnology*, 7:394 (1989).

45

30 Other types of "antibodies" can be produced using the information provided herein in conjunction with the state of knowledge in the art. For example, antibodies that have been engineered to contain elements of human antibodies that are capable of specifically binding polypeptides of the invention are also encompassed by the invention.

50

55

5

Once isolated and purified, the antibodies against polypeptides of the invention can be used to detect the presence of the polypeptides in a sample using established assay protocols. Further, the antibodies of the invention can be used therapeutically or for research purposes to bind to the polypeptides and inhibit its activity *in vivo* or *in vitro*.

10

5 Antibodies immunoreactive with polypeptides of the invention, and in particular, monoclonal antibodies against these polypeptides, are now made available through the invention. Such antibodies can be useful for inhibiting polypeptide activity *in vivo* and for detecting the presence of polypeptides of the invention in a sample.

15

10 In another embodiment, antibodies generated against a polypeptide and fragmented peptides of the invention can be used in combination with polypeptide or fragmented peptide molecular weight markers of the invention to enhance the accuracy in 20 the use of these molecular weight markers to determine the apparent molecular weight and isoelectric point of a sample protein. Polypeptide or fragmented peptide molecular weight markers of the invention can be mixed with a molar excess of a sample protein 25 and the mixture can be resolved by two dimensional electrophoresis by conventional means. Polypeptides can be transferred to a suitable protein binding membrane, such as nitrocellulose, by conventional means and detected by the antibodies of the invention.

30

30 The purified polypeptides according to the invention will facilitate the discovery 20 of inhibitors of such polypeptides. The use of a purified polypeptide of the invention in the screening of potential inhibitors thereof is important and can eliminate or reduce the 35 possibility of interfering reactions with contaminants.

35

35 In addition, polypeptides of the invention can be used for structure-based design 40 of polypeptide-inhibitors. Such structure-based design is also known as "rational drug 25 design." The polypeptides can be three-dimensionally analyzed by, for example, X-ray crystallography, nuclear magnetic resonance or homology modeling, all of which are well-known methods. The use of the polypeptide structural information in molecular 45 modeling software systems to assist in inhibitor design and inhibitor- polypeptide interaction is also encompassed by the invention. Such computer-assisted modeling and drug design can utilize information such as chemical conformational analysis, 50 electrostatic potential of the molecules, protein folding, etc. For example, most of the design of class-specific inhibitors of metalloproteases has focused on attempts to chelate or bind the catalytic zinc atom. Synthetic inhibitors are usually designed to contain a negatively-charged moiety to which is attached a series of other groups designed to fit the specificity pockets of the particular protease. A particular method of the invention

5

comprises analyzing the three dimensional structure of polypeptides of the invention for likely binding sites of substrates, synthesizing a new molecule that incorporates a predictive reactive site, and assaying the new molecule as described above.

10

The polypeptides of the present invention may also be used in a screening assay to identify compounds and small molecules which inhibit (antagonize) or enhance (agonize) activation of the polypeptides of the instant invention. Thus, for example, polypeptides of the invention may be used to identify antagonists and agonists from cells, cell-free preparations, chemical libraries, and natural product mixtures. The antagonists and agonists may be natural or modified substrates, ligands, enzymes, receptors, etc. of the polypeptides of the instant invention, or may be structural or functional mimetics of the polypeptides. Potential antagonists of the polypeptides of the instant invention may include small molecules, peptides, and antibodies that bind to and occupy a binding site of the polypeptides, causing them to be unavailable to bind to their ligands and therefore preventing normal biological activity. Other potential antagonists are antisense molecules which may hybridize to mRNA *in vivo* and block translation of the mRNA into the polypeptides of the instant invention. Potential agonists include small molecules, peptides and antibodies which bind to the instant polypeptides and elicit the same or enhanced biological effects as those caused by the binding of the polypeptides of the instant invention.

30

20 Small molecule agonists and antagonists are usually less than 10K molecular weight and may possess a number of physiochemical and pharmacological properties that enhance cell penetration, resist degradation and prolong their physiological half-lives.

35

(Gibbs, J., Pharmaceutical Research in Molecular Oncology, *Cell*, Vol. 79 (1994).)

40

Antibodies, which include intact molecules as well as fragments such as Fab and F(ab')<sup>2</sup> fragments, may be used to bind to and inhibit the polypeptides of the instant invention by blocking the commencement of a signaling cascade. It is preferable that the antibodies are humanized, and more preferable that the antibodies are human. The antibodies of the present invention may be prepared by any of a variety of well-known methods.

45

Specific screening methods are known in the art and many are extensively incorporated in high throughput test systems so that large numbers of test compounds can be screened within a short amount of time. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays, cell based assays, etc. These assay formats are well known in the art.

50

The screening assays of the present invention are amenable to screening of chemical

5       libraries and are suitable for the identification of small molecule drug candidates,  
10      antibodies, peptides and other antagonists and agonists.

      One embodiment of a method for identifying molecules which antagonize or  
15      inhibit the polypeptides involves adding a candidate molecule to a medium which  
20      5     contains cells that express the polypeptides of the instant invention; changing the  
25      conditions of said medium so that, but for the presence of the candidate molecule, the  
30      polypeptides would be bound to their ligands; and observing the binding and stimulation  
35      or inhibition of a functional response. The activity of the cells which were contacted with  
40      the candidate molecule may then be compared with the identical cells which were not  
45      contacted and agonists and antagonists of the polypeptides of the instant invention may be  
50      identified. The measurement of biological activity may be performed by a number of  
55      well-known methods such as measuring the amount of protein present (e.g. an ELISA) or  
60      of the protein's activity. A decrease in biological stimulation or activation would  
65      indicate an antagonist. An increase would indicate an agonist. Specifically, one  
70      embodiment of the instant invention includes agonists and antagonists of QQ3351,  
75      SS1771, SS1771A and truncated QQ3351.

      Screening assays can further be designed to find molecules that mimic the  
10      biological activity of the polypeptides of the instant invention. Molecules which mimic  
15      the biological activity of a polypeptide may be useful for enhancing the biological activity  
20      20     of the polypeptide. To identify compounds for therapeutically active agents that mimic  
25      the biological activity of a polypeptide, it must first be determined whether a candidate  
30      molecule binds to the polypeptide. A binding candidate molecule is then added to a  
35      biological assay to determine its biological effects. The biological effects of the  
40      candidate molecule are then compared to the those of the polypeptide.

      25     The specification is most thoroughly understood in light of the teachings of the  
40      references cited within the specification, which are hereby incorporated by reference.  
45      The embodiments within the specification provide an illustration of embodiments of the  
50      invention and should not be construed to limit the scope of the invention. The skilled  
55      artisan recognizes many other embodiments are encompassed by the claimed invention.

45

50

**Claims**

5

10

15

20

25

30

35

40

45

50

55

5

What is claimed is:

1. An isolated nucleic acid molecule comprising the DNA of SEQ ID NO:1, 2, 3, 4, 5, 6, 13 and 15.

10

2. An isolated nucleic acid molecule encoding an amino acid sequence comprising the sequence of SEQ ID NO:7, 8, 9, 10, 11, 12, 14 and 16.

15

3. An isolated nucleic acid molecule that hybridizes to either strand of a denatured, double-stranded DNA comprising the nucleic acid sequence of any one of claims 1 or 2 under conditions of moderate stringency in 50% formamide and 6XSSC, at 42°C with washing conditions of 60°C, 0.5XSSC, 0.1% SDS.

20

4. The isolated nucleic acid molecule as claimed in claim 3, wherein said isolated nucleic acid molecule is derived by *in vitro* mutagenesis from SEQ ID NO: 1, 2, 3, 4, 5, 6, 13 and 15.

25

5. An isolated nucleic acid molecule degenerate from SEQ ID NO: 1, 2, 3, 4, 5, 6, 13 and 15 as a result of the genetic code.

30

6. An isolated nucleic acid molecule, which is human DNA, an allelic variant of human DNA, or a species homolog of DNA selected from the group consisting of HH0900, HH2040, JJ503, QQ1249, QQ3351, QQ3351 (truncated), SS1771, and 35 SS1771A.

35

7. A recombinant vector that directs the expression of a nucleic acid molecule selected from the group consisting of the nucleic acid molecules of claims 1, 2, 5, and 6.

40

8. A recombinant vector that directs the expression of a nucleic acid molecule of claim 3.

45

9. A recombinant vector that directs the expression of a nucleic acid molecule of claim 4.

50

5

10. An isolated polypeptide encoded by a nucleic acid molecule selected from the group consisting of the nucleic acid molecules of claims 1, 2, 5, and 6.

10

11. An isolated polypeptide according to claim 10 having a molecular weight of approximately 6883; 8168; 39,284; 16,718; 58,001; 57,381; and 67,331 Daltons as determined by SDS-PAGE.

15

12. An isolated polypeptide according to claim 10 in non-glycosylated form.

13. An isolated polypeptide encoded by a nucleic acid molecule of claim 3.

20

14. An isolated polypeptide according to claim 13 in non-glycosylated form.

15. An isolated polypeptide encoded by a nucleic acid molecule of claim 4.

25

16. An isolated polypeptide according to claim 15 in non-glycosylated form.

17. Isolated antibodies that bind to a polypeptide of claim 10.

30

18. Isolated antibodies according to claim 17, wherein the antibodies are monoclonal antibodies.

35

19. Isolated antibodies that bind to a polypeptide of claim 13.

20. Isolated antibodies according to claim 19, wherein the antibodies are monoclonal antibodies.

40

21. Isolated antibodies that bind to a polypeptide of claim 15.

45

22. Isolated antibodies according to claim 21, wherein the antibodies are monoclonal antibodies.

23. A host cell transfected or transduced with the vector of claim 7.

50

5

24. A method for the production of polypeptide comprising culturing a host cell of claim 23 under conditions promoting expression, and recovering the polypeptide from the culture medium.

10

25. The method of claim 24, wherein the host cell is selected from the group consisting of bacterial cells, yeast cells, plant cells, insect cells, and animal cells.

15

26. A host cell transfected or transduced with the vector of claim 8.

20

27. A method for the production of polypeptide comprising culturing a host cell of claim 26 under conditions promoting expression, and recovering the polypeptide from the culture medium.

25

28. The method of claim 27, wherein the host cell is selected from the group consisting of bacterial cells, yeast cells, plant cells, insect cells, and animal cells.

30

29. A host cell transfected or transduced with the vector of claim 9.

30. A method for the production of polypeptide comprising culturing a host cell of claim 29 under conditions promoting expression, and recovering the polypeptide from the culture medium.

35

31. The method of claim 30, wherein the host cell is selected from the group consisting of bacterial cells, yeast cells, plant cells, and animal cells.

40

32. A method of screening a candidate molecule to identify its ability to inhibit (antagonize) or agonize a polypeptide encoded by cDNA selected from the group consisting of SEQ. ID. NO.:1, 2, 3, 4, 5, 6, 13 and 15, said method comprising the steps of:

45

(a) adding said candidate molecule to a medium which contains cells expressing said polypeptide;

(b) changing the conditions of said medium so that, but for the presence of said candidate molecule, said polypeptide would be bound;

50

5

- (c) determining the level of biological activity of said polypeptide formed in said medium; and
- (d) comparing the level of biological activity of step (c) with the level of biological activity that occurs in said medium in the absence of said candidate molecule;

10

wherein a decreased level of biological activity of step (c) as compared to the level of biological activity that occurs in said medium in the absence of said candidate molecule indicates an antagonist and an increased level of biological activity indicates an agonist.

15

33. An antagonist as identified by the method of claim 32.

20

34. The antagonist of claim 33, wherein said cDNA is selected from the group consisting of SEQ.ID. NO.: 5, 6, 13 and 15.

25

35. An agonist as identified by the method of claim 32.

30

36. A method of screening a candidate molecule to identify its ability to mimic the biological activity of a polypeptide encoded by cDNA selected from the group consisting of SEQ. ID. NO.:1, 2, 3, 4, 5, 6, 13 or 15, said method comprising the steps of :

35

- a. determining if said candidate molecule binds to said polypeptide or fragments thereof;
- b. adding said candidate molecule to a biological assay to determine its biological effects; and
- c. comparing said biological effects of said candidate molecule with the biological effects of said polypeptide.

40

45

50

## SEQUENCE LISTING

5       <110> Virca, Duke  
          Bird, Timothy A.  
5        Anderson, Dirk M.  
      Marken, John S.  
      Immunex Corporation

10      <120> Human DNA and Polypeptides Having Kinase Functions  
10      <130> 2877-WO

15      <140> --to be assigned--  
15      <141> 1999-08-03

20      <150> 60/099,972  
20      <151> 1998-09-11

25      <150> 60/095,270  
25      <151> 1998-08-04

30      <160> 12

35      <170> PatentIn Ver. 2.0

35      <210> 1  
35      <211> 181  
35      <212> DNA  
35      <213> Homo sapiens

40      <400> 1  
40      gtacgccccatg aagggtgtgc gcaaggcgcc gctgggtgcag cgcgccaaaga cgcaagagca 60  
40      cacgcgcacc gagcgctgg tggcggact ggtgcggccag ggcgcctcc tggtcacgc 120  
40      gcactacgct ttccagacgg atgccaagct gcacccatc ctggactatg tgagcggcgg 180  
40      g 181

45      <210> 2  
45      <211> 221  
45      <212> DNA  
45      <213> Homo sapiens

50      <400> 2  
50      cccgagaggt gcccacatcag accgcctccg acttcgtgcg ggactcgccg gcccggccacc 60  
50      aggcgaggcc cgaggcgatc gagcgccgcg tggcgttccct gttctgcac 120  
50      ggctggagca cctgaaggag cacggatca tccacccggta cctgtgcctg gagaacctgc 180  
50      tgctggtgca ctgcacccctc caggccggcc cccggccgc 221

55      <210> 3  
55      <211> 1085  
55      <212> DNA  
55      <213> Homo sapiens

60      <400> 3  
60      cgggcaggcc tggagctggg ctggatccc gagctggca gcagcgcagc gggccggccc 60  
60      acctgtgtt gcccgtggg ctctgagccc cggcgccgc cggcccccacg cggaaacgc 120  
60      gggcgagatg cgagccaccc ctctggctgc tcctgcgggt tccctgtcca ggaagaagcg 180  
60      gttggagtt gatgacaact tagatccga gctcccgta cagaaacgag ctcgaagtgg 240  
60      gccccagccc agactgcccc cctgctgtt gcccgtggc ccacactatg ctccagatcg 300  
60      tgcaactgct tggccactg cctccgtct tggccctat gtctcctgg agcccggag 360  
60      ggcgccggcc gcttaccagg ccctgcactg ccctacaggc actgagtata cctgcaagg 420

gtaccccgctc	caggaagccc	tggccgtgct	ggagccctac	gcgcggctgc	ccccgcacaa	480
gcatgtggct	cggcccaactg	aggctctggc	tggtaaaaaag	ctctctctacg	cctttttcac	540
tcggaccat	ggggacatgc	acagctgtgg	gcggaaaggcgc	cacggatattcc	ctgagccctga	600
ggctggcggt	cttttcggcc	atggatggcc	cgccccggcg	cactgtcacc	agcagcggct	660
ggtctcgctg	gatctcaaaag	tgtgtcgctt	tgtcttcgtc	gaccgtgaga	ggaaaagaatg	720
ggtgctggag	aacctggagg	actctcgct	gctgactgggg	ccagatgatt	ccctgtggga	780
caagcacgcg	tgcccagct	acgtgggacc	tgagataactc	agtcacggg	cctcataactc	840
gggcggggca	gccgatgttt	ggagccctggg	cgtggcgctc	ttaaccatgc	tggccggcca	900
ctacccttc	caggacttcgg	aggctgtctt	gcttttcggc	aagatcccccc	gccccggccca	960
cgccctgcct	gcaggcctt	cggccctgc	ccgtgtctg	gttcgtgccc	tcttcgtcgc	1020
ggaggccagct	gaacggctca	cagccacagg	catccctctg	ccccctggc	tgcgcacagg	1080
ccccga						1085

<210> 4  
<211> 388  
<212> DNA  
<213> *Homo sapiens*

```
<400> 4
cagcgagaag ccgacatgca tcgccttcc aatcacccca acatccttcg cctcgtggct 60
tactgtctga gggAACgggg tgctaagcat gaggcctggc tgctgttacc attcttcaag 120
agaggatcacg tggatataa gatagaaaagg ctgaaaggaca aaggcaactt cctgaccggag 180
gatcaaattcc ttgggtgtct gctggggatc tgcaagggcc ttggggccat tcatggccaa 240
ggttatgcctt acagagactt gaagccccacc aataatattgc ttggagatga ggggcagcca 300
gtttatgttgg accttgggttc catgaatcaa gcatgcattt atgtggaggg cttccgcagg 360
gctctgaccc tgcaaggactg ggcagcccc 388
```

<210> 5  
<211> 1555  
<212> DNA  
<213> *Homo sapiens*

```

<400> 5
atgctaacta gtttaaacag atcttggAAC gagacgacct gctgtggAG agcgagCTT 60
ttggactgt gcacggcaca gattggacgc acacccCTG ggaggcgcga aggcatggaa 120
aatttgaagc attattatcac ccttggccAG gtcatccaca aacggtgtga agagatgaaa 180
tactcgaaAG aacatgtGCCG gcgcgtggc cacccgcgtcc tcggcctgtat caagccttc 240
gagatgtccc aggaccaagg aaagaggAGC gtggcccttg agaagttAAC cacagccatg 300
aaccgcTTCA aggctggcCTT ggaggaggCT aatggggaga tagaaaaAGT cagcaatAGA 360
tccaaatTCG gcaggTTCTT aacacgaaAG cggacaaaaa tacttccaa ggacgtgaaAC 420
aggaagctGA gtgtatgtCTG gaaggagCTC tcgtgttAC tcagggttGA gcaacgcATG 480
ccttggccAC ctaaAGGCCA aggacgtCC tgggcacAG aagatcAGCA ggatgcAGAC 540
gaagacaggc gagcttcca gatgtcaAGA agagataATG aaaaaatAGA agttcaCTG 600
agacgattAG aaatcaacAT gaaAGAAATC aaggAAACCT tgaggcAGTA ttaccacCA 660
aaatgcATGc aggagatccc gcaagAGCA aatcaaggAGA tcaagaAGGA gcagcttCC 720
ggatccccGT ggattctGT aaggaaaaAT gaagtcaGCA cactttataa aggagaatac 780
cacagagCTC cagtggccAT aaaaatTC aaaaactCC aggtggcAG catrGcaAT 840
gtggcaggcA ctgtcaataa ggagatCAAA accatgtAGA aattcGAATC tcccaacATC 900
ctgcgtatAT ttgggattTG cattgtGAAG acagtGACTC cgcCTCAATT ctccattGTc 960
atggagtACT gtgaactCGG gaccCTGAGG gagctgttGG ataggaaaaAG acacctcaca 1020
cttggcaAGC gcatggCTT agtCTGGGG gcagccccAG gccttataCC gctacacatC 1080
tcagaagcAC ctgaaCTCA cggaaaaATC agaaGTCTAA attcttCTGT aactcaaggC 1140
taccaagtgA agcttgcAGG atttgatgtG agggaaaaAC agatcttCCAT gagtttGGG 1200
actacgagAG aaaaagacAGA cagagtCAAA tctacAGCAT atctctcACC tcaggaACTG 1260
gaagatgtAT ttatcaATA tgatgtAAAG tctgaaATAT acagtttGG aatcgTCCTC 1320
tggggaaATCG ccactggAGA tatCCCTTt caaggctgtA attcttgAGAA gatccGcaAG 1380
ctgggtggCTG tgaaggcgcA gcaggAGcCA ctgggtGAAG actggccCTC agagctGcGG 1440
gagatcatTG atgatgtGCCG ggcagcAGGT cgtctcgTT caagatGTt agcggccGCC 1500
cggggccTcG acGTTTAAAC cgtgtggccCT cggaggttT tccgatccGG tcgtat 1555

```

<210> 6  
 <211> 1498  
 <212> DNA  
 <213> Homo sapiens

<400> 6  
 cttcccgctg gacgtggagt acggaggccc agaccggagg tgcccgctc cgccctaccc 60  
 gaagcacctg ctgctgcgca gcaagtgcgga gcagtcgac ctggacagcc tgcgcagg 120  
 catggagcag agcctccgtg cgggccccaa cgagcccgag ggccgcgaca agagccgaa 180  
 aaggcacaag ggggacaaaag gccggaaagga taaaaagcag attcagaccc ctcccggtcc 240  
 cgtccgcaaa aacagcagag acgaagagaa gagagagtca cgcataaga gctactcgcc 300  
 atacgcctt aagttctca tggacgacca cgtggagaat gtcataaaa cctaccgca 360  
 gaaggtaac cgaggctgc agctggagca agaaatggcc aaagctggac tctgtgaagc 420  
 tgagcaggag cagatgcgga agatcctcta ccagaaaagag tctaattaca acaggtaaa 480  
 gaggccaaag attggacaatg ctatgtttgt caagatcaa accctgggg tcgggtcc 540  
 tggagaatgt tgccctgtt gtaagggttga cactcaccc ctgtacgcca tgaagaccc 600  
 aagaaaaaaag gatgtcctga accggaaatca ggtggccca gtcgaaggcc agaggacat 660  
 cctggccag gcagacaatg agtgggtgtt caaactctac tactccttcc aagacaaaaga 720  
 cagcctgtac ttgtgtatgg actacatccc tggtggggac atgatgagcc tgctgatcc 780  
 gatggaggtc ttccctgagc acctggccct gttctacatc gcagagctga ctttggccat 840  
 tggaggtgtc cacaagatgg gttcatcca ccgagacatc aagectgata acatttgat 900  
 agatctggat ggtcacattha aactcacaga tttcggccctc tgcaactgggt tcagggtgac 960  
 tcacaattcc aaatattacc agaaaaggag ccatgtcaga caggacagca tggagccag 1020  
 cgacctctgg gatgtatgtt ctaactgtcg gtgtggggac aggctgaaga ccctagagca 1080  
 gagggcgcgg aagcagcacc agaggtgcctt ggcacatca ctggtggggc ctccaaacta 1140  
 catccgcaccc gaggtgtcc tccgcacaaagg gtacactcaa ctctgtact ggtggagtgt 1200  
 tggagtgtt ctcttcgaga tgctgggtggc gcagccgcctt ttttggcac ctactccac 1260  
 agaaacccag ctgaagggtt tcaactggga gaacacgttc cacattccag cccaggtgaa 1320  
 gctgagccctt gaggccaggg acctcatcac caagctgtgc tgctccgcag accacccct 1380  
 ggggcggaat gggcccgatg acctgaaggc ccaccccttc ttcaagcgcctt ttgacttttc 1440  
 cagtgacatc cggaaagcata cagcccccttca cgttcccccacc atcagccacc ccatggag 1498

<210> 7  
 <211> 60  
 <212> PRT  
 <213> Homo sapiens

<400> 7  
 Tyr Ala Met Lys Val Leu Arg Lys Ala Ala Leu Val Gln Arg Ala Lys  
 1 5 10 15  
 Thr Gln Glu His Thr Arg Thr Glu Arg Ser Val Leu Glu Leu Val Arg  
 20 25 30  
 Gln Ala Pro Phe Leu Val Thr Leu His Tyr Ala Phe Gln Thr Asp Ala  
 35 40 45  
 Lys Leu His Leu Ile Leu Asp Tyr Val Ser Gly Gly  
 50 55 60

<210> 8  
 <211> 73  
 <212> PRT  
 <213> Homo sapiens

<400> 8  
 Arg Glu Val Pro His Gln Thr Ala Ser Asp Phe Val Arg Asp Ser Ala  
 1 5 10 15

Ala Ser His Gln Ala Glu Pro Glu Ala Tyr Glu Arg Arg Val Cys Phe  
20 25 30

Leu Leu Leu Gln Leu Cys Asn Gly Leu Glu His Leu Lys Glu His Gly  
35 40 45

Ile Ile His Arg Asp Leu Cys Leu Glu Asn Leu Leu Leu Val His Cys  
50 55 60

Thr Leu Gln Ala Gly Pro Gly Pro Ala  
65 70

<210> 9  
<211> 360  
<212> PRT  
<213> Homo sapiens

<400> 9  
Gly Gln Gly Trp Ser Trp Ala Gly Ile Pro Ser Ser Ala Ala Ala Gln  
1 5 10 15

Arg Ala Gly Pro Pro Ala Gly Ala Leu Glu Ala Leu Ser Pro Gly Gly  
20 25 30

Ala Arg Ala His Ala Glu Arg Arg Gly Glu Met Arg Ala Thr Pro Leu  
35 40 45

Ala Ala Pro Ala Gly Ser Leu Ser Arg Lys Lys Arg Leu Glu Leu Asp  
50 55 60

Asp Asn Leu Asp Thr Glu Arg Pro Val Gln Lys Arg Ala Arg Ser Gly  
65 70 75 80

Pro Gln Pro Arg Leu Pro Pro Cys Leu Leu Pro Leu Ser Pro Pro Thr  
85 90 95

Ala Pro Asp Arg Ala Thr Ala Val Ala Thr Ala Ser Arg Leu Gly Pro  
100 105 110

Tyr Val Leu Leu Glu Pro Glu Glu Gly Arg Ala Tyr Gln Ala Leu  
115 120 125

His Cys Pro Thr Gly Thr Glu Tyr Thr Cys Lys Val Tyr Pro Val Gln  
130 135 140

Glu Ala Leu Ala Val Leu Glu Pro Tyr Ala Arg Leu Pro Pro His Lys  
145 150 155 160

His Val Ala Arg Pro Thr Glu Val Leu Ala Gly Thr Gln Leu Leu Tyr  
165 170 175

Ala Phe Phe Thr Arg Thr His Gly Asp Met His Ser Leu Val Arg Ser  
180 185 190

Arg His Arg Ile Pro Glu Pro Glu Ala Ala Val Leu Phe Arg Gln Met  
195 200 205

Ala Thr Ala Leu Ala His Cys His Gln His Gly Leu Val Leu Arg Asp  
210 215 220

Leu Lys Leu Cys Arg Phe Val Phe Ala Asp Arg Glu Arg Lys Lys Leu  
 225 230 235 240

Val Leu Glu Asn Leu Glu Asp Ser Cys Val Leu Thr Gly Pro Asp Asp  
 245 250 255

Ser Leu Trp Asp Lys His Ala Cys Pro Ala Tyr Val Gly Pro Glu Ile  
 260 265 270

Leu Ser Ser Arg Ala Ser Tyr Ser Gly Lys Ala Ala Asp Val Trp Ser  
 275 280 285

Leu Gly Val Ala Leu Phe Thr Met Leu Ala Gly His Tyr Pro Phe Gln  
 290 295 300

Asp Ser Glu Pro Val Leu Leu Phe Gly Lys Ile Arg Arg Gly Ala Tyr  
 305 310 315 320

Ala Leu Pro Ala Gly Leu Ser Ala Pro Ala Arg Cys Leu Val Arg Cys  
 325 330 335

Leu Leu Arg Arg Glu Pro Ala Glu Arg Leu Thr Ala Thr Gly Ile Leu  
 340 345 350

Leu His Pro Trp Leu Arg Gln Asp  
 355 360

<210> 10  
 <211> 146  
 <212> PRT  
 <213> Homo sapiens

<400> 10  
 Gln Arg Glu Ala Asp Met His Arg Leu Phe Asn His Pro Asn Ile Leu  
 1 5 10 15

Arg Leu Val Ala Tyr Cys Leu Arg Glu Arg Gly Ala Lys His Glu Ala  
 20 25 30

Trp Leu Leu Leu Pro Phe Phe Lys Arg Gly Thr Leu Trp Asn Glu Ile  
 35 40 45

Glu Arg Leu Lys Asp Lys Gly Asn Phe Leu Thr Glu Asp Gln Ile Leu  
 50 55 60

Trp Leu Leu Leu Gly Ile Cys Arg Gly Leu Glu Ala Ile His Ala Lys  
 65 70 75 80

Gly Tyr Ala Tyr Arg Asp Leu Lys Pro Thr Asn Ile Leu Leu Gly Asp  
 85 90 95

Glu Gly Gln Pro Val Leu Met Asp Leu Gly Ser Met Asn Gln Ala Cys  
 100 105 110

Ile His Val Glu Gly Ser Arg Gln Ala Leu Thr Leu Gln Asp Trp Ala  
 115 120 125

Ala Gln Arg Cys Thr Ile Ser Tyr Arg Ala Pro Xaa Leu Phe Ser Val  
 130 135 140

Gln Ser  
 145

<210> 11  
 <211> 505  
 <212> PRT  
 <213> Homo sapiens

<400> 11  
 Met Leu Thr Ser Leu Asn Arg Ser Trp Asn Glu Thr Thr Cys Cys Gly  
 1 5 10 15

Arg Ala Ser Phe Leu Glu Leu Cys Thr Gly Gln Ile Gly Arg Thr Pro  
 20 25 30

Leu Gly Arg Arg Glu Gly Met Glu Asn Leu Lys His Ile Ile Thr Leu  
 35 40 45

Gly Gln Val Ile His Lys Arg Cys Glu Glu Met Lys Tyr Cys Lys Lys  
 50 55 60

Gln Cys Arg Arg Leu Gly His Arg Val Leu Gly Leu Ile Lys Pro Leu  
 65 70 75 80

Glu Met Leu Gln Asp Gln Gly Lys Arg Ser Val Pro Ser Glu Lys Leu  
 85 90 95

Thr Thr Ala Met Asn Arg Phe Lys Ala Ala Leu Glu Glu Ala Asn Gly  
 100 105 110

Glu Ile Glu Lys Phe Ser Asn Arg Ser Asn Ile Cys Arg Phe Leu Thr  
 115 120 125

Ala Ser Gln Asp Lys Ile Leu Phe Lys Asp Val Asn Arg Lys Leu Ser  
 130 135 140

Asp Val Trp Lys Glu Leu Ser Leu Leu Gln Val Glu Gln Arg Met  
 145 150 155 160

Pro Val Ser Pro Ile Ser Gln Gly Ala Ser Trp Ala Gln Glu Asp Gln  
 165 170 175

Gln Asp Ala Asp Glu Asp Arg Arg Ala Phe Gln Met Leu Arg Arg Asp  
 180 185 190

Asn Glu Lys Ile Glu Ala Ser Leu Arg Arg Leu Glu Ile Asn Met Lys  
 195 200 205

Glu Ile Lys Glu Thr Leu Arg Gln Tyr Leu Pro Pro Lys Cys Met Gln  
 210 215 220

Glu Ile Pro Gln Glu Gln Ile Lys Glu Ile Lys Lys Glu Gln Leu Ser  
 225 230 235 240

Gly Ser Pro Trp Ile Leu Leu Arg Glu Asn Glu Val Ser Thr Leu Tyr  
 245 250 255

Lys Gly Glu Tyr His Arg Ala Pro Val Ala Ile Lys Val Phe Lys Lys  
 260 265 270  
 Leu Gln Ala Gly Ser Ile Ala Ile Val Arg Gln Thr Phe Asn Lys Glu  
 275 280 285  
 Ile Lys Thr Met Lys Lys Phe Glu Ser Pro Asn Ile Leu Arg Ile Phe  
 290 295 300  
 Gly Ile Cys Ile Asp Glu Thr Val Thr Pro Pro Gln Phe Ser Ile Val  
 305 310 315 320  
 Met Glu Tyr Cys Glu Leu Gly Thr Leu Arg Glu Leu Leu Asp Arg Glu  
 325 330 335  
 Lys Asp Leu Thr Leu Gly Lys Arg Met Val Leu Val Leu Gly Ala Ala  
 340 345 350  
 Arg Gly Leu Tyr Arg Leu His His Ser Glu Ala Pro Glu Leu His Gly  
 355 360 365  
 Lys Ile Arg Ser Ser Asn Phe Leu Val Thr Gln Gly Tyr Gln Val Lys  
 370 375 380  
 Leu Ala Gly Phe Glu Leu Arg Lys Thr Gln Thr Ser Met Ser Leu Gly  
 385 390 395 400  
 Thr Thr Arg Glu Lys Thr Asp Arg Val Lys Ser Thr Ala Tyr Leu Ser  
 405 410 415  
 Pro Gln Glu Leu Glu Asp Val Phe Tyr Gln Tyr Asp Val Lys Ser Glu  
 420 425 430  
 Ile Tyr Ser Phe Gly Ile Val Leu Trp Glu Ile Ala Thr Gly Asp Ile  
 435 440 445  
 Pro Phe Gln Gly Cys Asn Ser Glu Lys Ile Arg Lys Leu Val Ala Val  
 450 455 460  
 Lys Arg Gln Gln Glu Pro Leu Gly Glu Asp Cys Pro Ser Glu Leu Arg  
 465 470 475 480  
 Glu Ile Ile Asp Glu Cys Arg Ala Ala Gly Arg Leu Val Pro Arg Ser  
 485 490 495  
 Val Ala Ala Ala Arg Ala Val Asp Val  
 500 505

<210> 12  
 <211> 499  
 <212> PRT  
 <213> Homo sapiens

<400> 12  
 Phe Pro Leu Asp Val Glu Tyr Gly Pro Asp Arg Arg Cys Pro Pro  
 1 5 10 15

Pro Pro Tyr Pro Lys His Leu Leu Leu Arg Ser Lys Ser Glu Gln Tyr  
 20 25 30  
 Asp Leu Asp Ser Leu Cys Ala Gly Met Glu Gln Ser Leu Arg Ala Gly  
 35 40 45  
 Pro Asn Glu Pro Glu Gly Gly Asp Lys Ser Arg Lys Ser Ala Lys Gly  
 50 55 60  
 Asp Lys Gly Gly Lys Asp Lys Lys Gln Ile Gln Thr Ser Pro Val Pro  
 65 70 75 80  
 Val Arg Lys Asn Ser Arg Asp Glu Glu Lys Arg Glu Ser Arg Ile Lys  
 85 90 95  
 Ser Tyr Ser Pro Tyr Ala Phe Lys Phe Met Glu Gln His Val Glu  
 100 105 110  
 Asn Val Ile Lys Thr Tyr Gln Gln Lys Val Asn Arg Arg Leu Gln Leu  
 115 120 125  
 Glu Gln Glu Met Ala Lys Ala Gly Leu Cys Glu Ala Glu Gln Glu Gln  
 130 135 140  
 Met Arg Lys Ile Leu Tyr Gln Lys Glu Ser Asn Tyr Asn Arg Leu Lys  
 145 150 155 160  
 Arg Ala Lys Met Asp Lys Ser Met Phe Val Lys Ile Lys Thr Leu Gly  
 165 170 175  
 Ile Gly Ala Phe Gly Glu Val Cys Leu Ala Cys Lys Val Asp Thr His  
 180 185 190  
 Ala Leu Tyr Ala Met Lys Thr Leu Arg Lys Lys Asp Val Leu Asn Arg  
 195 200 205  
 Asn Gln Val Ala His Val Lys Ala Glu Arg Asp Ile Leu Ala Glu Ala  
 210 215 220  
 Asp Asn Glu Trp Val Val Lys Leu Tyr Tyr Ser Phe Gln Asp Lys Asp  
 225 230 235 240  
 Ser Leu Tyr Phe Val Met Asp Tyr Ile Pro Gly Gly Asp Met Met Ser  
 245 250 255  
 Leu Leu Ile Arg Met Glu Val Phe Pro Glu His Leu Ala Arg Phe Tyr  
 260 265 270  
 Ile Ala Glu Leu Thr Leu Ala Ile Glu Ser Val His Lys Met Gly Phe  
 275 280 285  
 Ile His Arg Asp Ile Lys Pro Asp Asn Ile Leu Ile Asp Leu Asp Gly  
 290 295 300  
 His Ile Lys Leu Thr Asp Phe Gly Leu Cys Thr Gly Phe Arg Trp Thr  
 305 310 315 320  
 His Asn Ser Lys Tyr Tyr Gln Lys Gly Ser His Val Arg Gln Asp Ser  
 325 330 335

Met Glu Pro Ser Asp Leu Trp Asp Asp Val Ser Asn Cys Arg Cys Gly  
 340 345 350  
 Asp Arg Leu Lys Thr Leu Glu Gln Arg Ala Arg Lys Gln His Gln Arg  
 355 360 365  
 Cys Leu Ala His Ser Leu Val Gly Thr Pro Asn Tyr Ile Ala Pro Glu  
 370 375 380  
 Val Leu Leu Arg Lys Gly Tyr Thr Gln Leu Cys Asp Trp Trp Ser Val  
 385 390 395 400  
 Gly Val Ile Leu Phe Glu Met Leu Val Gly Gln Pro Pro Phe Leu Ala  
 405 410 415  
 Pro Thr Pro Thr Glu Thr Gln Leu Lys Val Ile Asn Trp Glu Asn Thr  
 420 425 430  
 Leu His Ile Pro Ala Gln Val Lys Leu Ser Pro Glu Ala Arg Asp Leu  
 435 440 445  
 Ile Thr Lys Leu Cys Cys Ser Ala Asp His Arg Leu Gly Arg Asn Gly  
 450 455 460  
 Ala Asp Asp Leu Lys Ala His Pro Phe Phe Ser Ala Ile Asp Phe Ser  
 465 470 475 480  
 Ser Asp Ile Arg Lys His Pro Ala Pro Tyr Val Pro Thr Ile Ser His  
 485 490 495  
 Pro Met Glu

<210> 13  
 <211> 375  
 <212> DNA  
 <213> Homo sapiens

<400> 13  
 ctgcaggat ttgagtttag gaaaacacag acttccatga gtttggaaac tacgagagaa 60  
 aagacagaca gagtc当地 tacagcatat ctctcacctc aggaacttggaa agatgtat 120  
 tatcaatatg atgtaaaatgc tgaaatatac agctttggaa tcgtcccttg gaaaatcgcc 180  
 actggagata tcccggttca aggctgtatac tctgagaaga tccgcaagct ggtggctgtg 240  
 aagcggcagc aggagccact gggtaagac tgccttcag agctgcggga gatcattgtat 300  
 gactgcccggg cccatgatcc ctctgtgcgg ccctctgtgg atgaaaatctt aaagaaaactc 360  
 tccacctttt ctaag 375

<210> 14  
 <211> 125  
 <212> PRT  
 <213> Homo sapiens

<400> 14  
 Leu Ala Gly Phe Glu Leu Arg Lys Thr Gln Thr Ser Met Ser Leu Gly  
 1 5 10 15  
 Thr Thr Arg Glu Lys Thr Asp Arg Val Lys Ser Thr Ala Tyr Leu Ser  
 20 25 30

Pro Gln Glu Leu Glu Asp Val Phe Tyr Gln Tyr Asp Val Lys Ser Glu  
 35 40 45

Ile Tyr Ser Phe Gly Ile Val Leu Trp Glu Ile Ala Thr Gly Asp Ile  
 50 55 60

Pro Phe Gln Gly Cys Asn Ser Glu Lys Ile Arg Lys Leu Val Ala Val  
 65 70 75 80

Lys Arg Gln Gln Glu Pro Leu Gly Glu Asp Cys Pro Ser Glu Leu Arg  
 85 90 95

Glu Ile Ile Asp Glu Cys Arg Ala His Asp Pro Ser Val Arg Pro Ser  
 100 105 110

Val Asp Glu Ile Leu Lys Lys Leu Ser Thr Phe Ser Lys  
 115 120 125

<210> 15  
 <211> 1961  
 <212> DNA  
 <213> Homo sapiens

<400> 15  
 tccccctgga cgtggagtac ggaggcccag accggagggtg cccgcctccg ccctacccga 60  
 agcacctgct gctcgccagc aagtccggagc agtacgacct ggacaggctg tgccgaggca 120  
 tggagcagag cctccgtgcg ggccccaacg agcccggagg cggcgcacaag agccgcacaaa 180  
 gccccaaggg ggacaaaggc ggaaaggata aaaaggcagat tcagacactt cccgttcccg 240  
 tccgcaaaaaa cagcagagac gaagagaaga gagagtcacg catcaagagc tactcgccat 300  
 acggctttaa gttcttcatg gagcagcagc tgccggatgt catcaaaacc taccaggaga 360  
 aggttaacccg gaggctgcag ctggagcaag aatggccaa agctggactc tgcgttgc 420  
 agcaggagca gatgcggaaat atcctctacc agaaagagtc taattacaac aggttaaaga 480  
 gggccaatgt ggacaatgtt atgtttgtca agatcaaaaac ccttggggatc ggtgccttt 540  
 gagaagtgtg ctttgcgtt aaggtggaca ctcacgcct gtacgcctatc aagaccctaa 600  
 gggaaaaggaa tggcttgcac cggatcagg tggccacatc aaggccggag agggacatcc 660  
 tggccgaggc agacaatgtg tgggtgtca aactctacta ctcccttccaa gacaaagaca 720  
 gcctgtactt tggatggac tacatccctg gtggggacat gatggactc ctgcgttgc 780  
 tggaggctt ccctggggac ctggccgggt tctacatccg agagctgact ttggccattt 840  
 agatgttca caagatggc ttcatccacc gagacatcaa gcctgtatc aatttgtatc 900  
 atctggatgg tcacatccaa ctccacaggat tggcccttc cactgggttc aggtggactc 960  
 acaattccaa atattaccag aaaggggagcc atgtcagaca ggacagcatg gagcccgacg 1020  
 acctctggaa tggatgttca aactgtccgtt gtggggacat gctgttgc 1080  
 gggccggaa gcagcaccatc aggtggctgg cacatccact ggtggggact ccaaactaca 1140  
 tcgcacccgg ggtgtccctc cgccaaagggtt acactcaat ctgtgttgc tggatgttt 1200  
 gagtgattttt cttcgatgtt ctggggggc agccggccctt tttggccacatc actccacag 1260  
 aaacccagctt gaagggttgc aactggggata acacgttccca cattccagcc caggtaaagc 1320  
 tgagcccttga ggccaggac ctcatccatc agctgtgttgc ctccgcacac caccgcctgg 1380  
 ggcggaaatgg ggccgatgtac ctgttgcggcc accccctttt cagccgcatt gacttctcca 1440  
 gtgacatccgg gaagcatcca gccccttacg ttcccatc cagccacccatc atggacaccc 1500  
 cgaatttccaa cccctgtatc gaagaaaggcc ctggaaacgc tgccgcggaa ggttagccaa 1560  
 aggccctggaa cacacttccac tcgcccataa acaagcatcc tgagccacgc ttttacaaat 1620  
 tcaccccttgc aagggttctt gatgacaatg gtcacccctt tcgtatcccc aagcccttc 1680  
 gagcagaagc ttcaacaggctt gagagcttcacg attttagaaat ctctgtatctg gtggatcaga 1740  
 ctgaaggctt cccgcctgtt tacgttgcgg tggggccgg gcaccccccac cactcgctgc 1800  
 ctcccaagggttccgg agccgggttgc ctcacaggcc aatagggaaat ccggggctg 1860  
 ttttgttttta aatttttttttgc tcgatattttt cacttgcattt ttcgttcttc accaagaaaa 1920  
 cccaaacagg acacttttgc aaacagccgtt gcccgcattt 1961

<210> 16  
<211> 588  
<212> PRT  
<213> Homo sapiens

<400> 16  
Pro Leu Asp Val Glu Tyr Gly Gly Pro Asp Arg Arg Cys Pro Pro Pro  
1 5 10 15  
Pro Tyr Pro Lys His Leu Leu Arg Ser Lys Ser Glu Gln Tyr Asp  
20 25 30  
Leu Asp Ser Leu Cys Ala Gly Met Glu Gln Ser Leu Arg Ala Gly Pro  
35 40 45  
Asn Glu Pro Glu Gly Gly Asp Lys Ser Arg Lys Ser Ala Lys Gly Asp  
50 55 60  
Lys Gly Gly Lys Asp Lys Lys Gln Ile Gln Thr Ser Pro Val Pro Val  
65 70 75 80  
Arg Lys Asn Ser Arg Asp Glu Glu Lys Arg Glu Ser Arg Ile Lys Ser  
85 90 95  
Tyr Ser Pro Tyr Ala Phe Lys Phe Phe Met Glu Gln His Val Glu Asn  
100 105 110  
Val Ile Lys Thr Tyr Gln Gln Lys Val Asn Arg Arg Leu Gln Leu Glu  
115 120 125  
Gln Glu Met Ala Lys Ala Gly Leu Cys Glu Ala Glu Gln Glu Gln Met  
130 135 140  
Arg Lys Ile Leu Tyr Gln Lys Glu Ser Asn Tyr Asn Arg Leu Lys Arg  
145 150 155 160  
Ala Lys Met Asp Lys Ser Met Phe Val Lys Ile Lys Thr Leu Gly Ile  
165 170 175  
Gly Ala Phe Gly Glu Val Cys Leu Ala Cys Lys Val Asp Thr His Ala  
180 185 190  
Leu Tyr Ala Met Lys Thr Leu Arg Lys Asp Val Leu Asn Arg Asn  
195 200 205  
Gln Val Ala His Val Lys Ala Glu Arg Asp Ile Leu Ala Glu Ala Asp  
210 215 220  
Asn Glu Trp Val Val Lys Leu Tyr Tyr Ser Phe Gln Asp Lys Asp Ser  
225 230 235 240  
Leu Tyr Phe Val Met Asp Tyr Ile Pro Gly Gly Asp Met Met Ser Leu  
245 250 255  
Leu Ile Arg Met Glu Val Phe Pro Glu His Leu Ala Arg Phe Tyr Ile  
260 265 270  
Ala Glu Leu Thr Leu Ala Ile Glu Ser Val His Lys Met Gly Phe Ile  
275 280 285

His Arg Asp Ile Lys Pro Asp Asn Ile Leu Ile Asp Leu Asp Gly His  
 290 295 300  
 Ile Lys Leu Thr Asp Phe Gly Leu Cys Thr Gly Phe Arg Trp Thr His  
 305 310 315 320  
 Asn Ser Lys Tyr Tyr Gln Lys Gly Ser His Val Arg Gln Asp Ser Met  
 325 330 335  
 Glu Pro Ser Asp Leu Trp Asp Asp Val Ser Asn Cys Arg Cys Gly Asp  
 340 345 350  
 Arg Leu Lys Thr Leu Glu Gln Arg Ala Arg Lys Gln His Gln Arg Cys  
 355 360 365  
 Leu Ala His Ser Leu Val Gly Thr Pro Asn Tyr Ile Ala Pro Glu Val  
 370 375 380  
 Leu Leu Arg Lys Gly Tyr Thr Gln Leu Cys Asp Trp Trp Ser Val Gly  
 385 390 395 400  
 Val Ile Leu Phe Glu Met Leu Val Gly Gln Pro Pro Phe Leu Ala Pro  
 405 410 415  
 Thr Pro Thr Glu Thr Gln Leu Lys Val Ile Asn Trp Glu Asn Thr Leu  
 420 425 430  
 His Ile Pro Ala Gln Val Lys Leu Ser Pro Glu Ala Arg Asp Leu Ile  
 435 440 445  
 Thr Lys Leu Cys Cys Ser Ala Asp His Arg Leu Gly Arg Asn Gly Ala  
 450 455 460  
 Asp Asp Leu Lys Ala His Pro Phe Phe Ser Ala Ile Asp Phe Ser Ser  
 465 470 475 480  
 Asp Ile Arg Lys His Pro Ala Pro Tyr Val Pro Thr Ile Ser His Pro  
 485 490 495  
 Met Asp Thr Ser Asn Phe Asp Pro Val Asp Glu Glu Ser Pro Trp Asn  
 500 505 510  
 Asp Ala Ser Glu Gly Ser Thr Lys Ala Trp Asp Thr Leu Thr Ser Pro  
 515 520 525  
 Asn Asn Lys His Pro Glu His Ala Phe Tyr Glu Phe Thr Phe Arg Arg  
 530 535 540  
 Phe Phe Asp Asp Asn Gly Tyr Pro Phe Arg Cys Pro Lys Pro Ser Gly  
 545 550 555 560  
 Ala Glu Ala Ser Gln Ala Glu Ser Ser Asp Leu Glu Ser Ser Asp Leu  
 565 570 575  
 Val Asp Gln Thr Glu Gly Cys Gln Pro Val Tyr Val  
 580 585



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification:</b> <b>C12N 15/55, C07K 16/40, C12N 9/12, G01N 33/50</b>		<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 00/08180</b> <b>(43) International Publication Date:</b> 17 February 2000 (17.02.2000)
<b>(21) International Application Number:</b> PCT/US99/17630			
<b>(22) International Filing Date:</b> 03 August 1999 (03.08.1999)		Published	
<b>(30) Priority Data:</b> 60/095,270 04 August 1998 (04.08.1998) US 60/099,972 11 September 1998 (11.09.1998) US			
<b>(60) Parent Application or Grant</b> IMMUNEX CORPORATION [/]; O. VIRCA, G., Duke [/]; O. BIRD, Timothy, A. [/]; O. ANDERSON, Dirk, M. [/]; O. MARKEN, John, S. [/]; O. VIRCA, G., Duke [/]; O. BIRD, Timothy, A. [/]; O. ANDERSON, Dirk, M. [/]; O. MARKEN, John, S. [/]; O. JONES, Simone, L. ; O.			
<b>(54) Title: HUMAN cDNAs ENCODING POLYPEPTIDES HAVING KINASE FUNCTIONS</b> <b>(54) Titre: ADNc HUMAINS CODANT DES POLYPEPTIDES A FONCTIONS KINASENS</b>			
<b>(57) Abstract</b>  The invention is directed to purified and isolated human polypeptides having kinase function, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, the use of such polypeptides and fragmented peptides in phosphorylation reactions and as molecular weight markers, the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, the use of such polypeptides in screening assays, and kits comprising these reagents.			
<b>(57) Abrégé</b>  La présente invention concerne des polypeptides humains isolés et purifiés à fonction kinase, les acides nucléiques codant ces polypeptides, des procédés de production de formes recombinées de ces polypeptides, des anticorps produits contre ces polypeptides, et des fragments de peptides obtenus à partir de ces polypeptides. Par ailleurs, cette invention concerne l'utilisation de ces polypeptides et des peptides fragmentés dans des réactions de phosphorylation et comme étalons de masse moléculaire, l'utilisation de ces polypeptides et des peptides fragmentés comme régulateurs de la fragmentation des peptides, l'utilisation de ces polypeptides dans des essais de dépistage, et enfin, des kits renfermant ces réactifs.			

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>7</sup> : <b>C12N 15/55, 9/12, C07K 16/40, G01N 33/50</b></p>		<p>A3</p>	<p>(11) International Publication Number: <b>WO 00/08180</b> (43) International Publication Date: 17 February 2000 (17.02.00)</p>
<p>(21) International Application Number: <b>PCT/US99/17630</b> (22) International Filing Date: 3 August 1999 (03.08.99)</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p>	
<p>(30) Priority Data: 60/095,270 4 August 1998 (04.08.98) US 60/099,972 11 September 1998 (11.09.98) US</p>		<p>(72) Inventors; and (75) Inventors/Applicants (for US only): VIRCA, G., Duke (US/US); 16690 S.E. 50th Place, Bellevue, WA 98006 (US). BIRD, Timothy, A. (GB/US); 10804 Olallie Drive N.E., Bainbridge Island, WA 98110 (US). ANDERSON, Dirk, M. (US/US); 3616 N.W. 64th Street, Seattle, WA 98107 (US). MARKEN, John, S. (US/US); 11804 9th Avenue S.W., Seattle, WA 98146 (US).</p>	
<p>(74) Agent: JONES, Simone, L.; Immunex Corporation, Law Dept., 51 University Street, Seattle, WA 98101 (US).</p>		<p>Published <i>With international search report.</i> (88) Date of publication of the international search report: 29 June 2000 (29.06.00)</p>	
<p>(54) Title: HUMAN cDNAs ENCODING POLYPEPTIDES HAVING KINASE FUNCTIONS</p>			
<p>(57) Abstract</p> <p>The invention is directed to purified and isolated human polypeptides having kinase function, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, the use of such polypeptides and fragmented peptides in phosphorylation reactions and as molecular weight markers, the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, the use of such polypeptides in screening assays, and kits comprising these reagents.</p>			

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## INTERNATIONAL SEARCH REPORT

International Application No  
PC, JS 99/17630A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12N15/55 C12N9/12 C07K16/40 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12N C07K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DEAK M. ET AL.: "Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38 and may mediate activation of CREB." EMBO JOURNAL, vol. 17, no. 15, 3 August 1998 (1998-08-03), pages 4426-4441, XP002126284 the whole document, especially Fig. 2 ---	1-32, 36
X	MARRA M. ET AL.: "The WashU-HHMI Mouse Project." EMBL DATABASE ENTRY MM1263730; ACCESSION NUMBER AA472165, 21 June 1997 (1997-06-21), XP002126285 abstract ---	1-16, 23-31 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*A\* document member of the same patent family

Date of the actual completion of the international search

20 December 1999

Date of mailing of the international search report

26.04.00

Name and mailing address of the ISA  
European Patent Office, P.O. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl  
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/JS 99/17630

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	PIERRAT B. ET AL.: "RSK-8, a novel ribosomal S6 kinase family member, is a CREB kinase under dominant control of p38(alpha) mitogen-activated protein kinase (p38(alpha)MAPK)." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 45, 6 November 1998 (1998-11-06), pages 29661-29671, XP002126286 the whole document -----	1-16, 23-31

1

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/17630

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: 33,34,35 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Claims 1-33,35,36 (all partially)

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 33,34,35

Claims 33,34 and 35 refer to antagonists and agonists of the polypeptides without giving a true technical characterization. Moreover, no such specific compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

and agonists of said polypeptide; and a method of screening a candidate molecule to identify its ability to mimic the biological activity of said polypeptide.

5. Claims: 1-36 (all partially)

A nucleic acid molecule comprising the DNA of SEQ.ID.5 or SEQ.ID.13; a vector containing said nucleic acid molecule; a polypeptide encoded by said nucleic acid molecule (as represented by SEQ.ID.11 or SEQ.ID.14); a nucleic acid molecule hybridizing with said nucleic acid molecule; antibodies specific for said polypeptide; a host cell containing said vector; methods for the production of said polypeptide; a method for screening for agonists or antagonists of said polypeptide; antagonists and agonists of said polypeptide; and a method of screening a candidate molecule to identify its ability to mimic the biological activity of said polypeptide.

6. Claims: 1-36 (all partially)

A nucleic acid molecule comprising the DNA of SEQ.ID.6; a vector containing said nucleic acid molecule; a polypeptide encoded by said nucleic acid molecule (as represented by SEQ.ID.12); a nucleic acid molecule hybridizing with said nucleic acid molecule; antibodies specific for said polypeptide; a host cell containing said vector; methods for the production of said polypeptide; a method for screening for agonists or antagonists of said polypeptide; antagonists and agonists of said polypeptide; and a method of screening a candidate molecule to identify its ability to mimic the biological activity of said polypeptide.

7. Claims: 1-9,11,13-16,19-36 (all partially)

A nucleic acid molecule comprising the DNA of SEQ.ID.15; a vector containing said nucleic acid molecule; a polypeptide encoded by said nucleic acid molecule (as represented by SEQ.ID.16); a nucleic acid molecule hybridizing with said nucleic acid molecule; antibodies specific for said polypeptide; a host cell containing said vector; methods for the production of said polypeptide; a method for screening for agonists or antagonists of said polypeptide; antagonists and agonists of said polypeptide; and a method of screening a candidate molecule to identify its ability to mimic the biological activity of said polypeptide.